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ABSTRACT 
NOVEL VIRAL AND ASTROCYTIC CONTRIBUTORS TO EPILEPSY 
 
Julie Chen 
Stewart A. Anderson 
 
Epilepsy is a neurological seizure disorder affecting approximately 1% of the world’s 
population. Seizure disorders are numerous, heterogeneous, and can develop from a 
multitude of physiological conditions including but not limited to interneuron 
dysfunction, ion channel mutations, irregular development and layering of the 
cerebral cortex, abnormalities in cell signaling pathways, brain tumors, traumatic 
brain injuries, and mitochondrial diseases. In many seizure disorders, gene mutations 
(primary) cause physiological abnormalities (secondary) that result in seizures. In 
some cases, the primary cause of epilepsy remains unknown, and in other cases, the 
secondary cause remains to be determined. My thesis research identified a novel, 
exogenous primary contributor to epilepsy in a specific subtype of cortical 
malformation disorders, as well as a secondary astrocytic irregularity resulting from a 
mitochondria-related nuclear gene mutation that may contribute to epilepsy. In 
Chapter 1, I briefly introduce the relationship between cortical malformation 
disorders, mitochondrial disease, and epilepsy. In Chapter 2, I present data supporting 
the idea that the cortical dyslamination and resultant epilepsy in focal cortical 
dysplasia type IIB is caused by the human papillomavirus oncoprotein E6. In Chapter 
3, I present data on astrocyte-specific irregularities resulting from mitochondrial 
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aspartate glutamate carrier loss of function and its effects on glutamatergic 
neurotransmission, and speculate on the role and importance of astrocytes in seizure 
genesis and propagation.  
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Chapter 1 
Introduction 
 
Epilepsy is a neurological seizure disorder defined by the recurrence of two or 
more unprovoked seizures more than 24 hours apart (Fisher et al., 2014). The first 
reports of epileptic patients can be traced back to Assyrian texts from 2,000 B.C., 
making epilepsy one of the oldest medical conditions described (Magiorkinis et al., 
2014). Today, more than 50 million people worldwide (approximately 1%) suffer 
from epilepsy, with the incidence on the rise (Banerjee et al., 2009). The study of 
epilepsy poses a unique challenge because it is a disorder with a singular set of 
symptoms (seizures) that can be caused by a multitude of physiological conditions, 
each of which may have their own causes. A PubMed search on causes of epilepsy 
yields numerous results: interneuron dysfunction, sodium channel mutations, cortical 
dyslamination, cellular signaling abnormalities, brain tumors, traumatic brain injury, 
and metabolic and/or mitochondrial dysregulation (Figure 1.1). My thesis research 
focused on identifying novel contributors to epilepsy and is divided into two chapters: 
1) identification of a viral element that causes cortical dyslamination; and 2) 
identification of an astrocytic irregularity resulting from mitochondrial dysfunction, 
which may contribute to abnormal glutamate neurotransmission underlying epilepsy. 
In the first part of this chapter, I introduce cortical lamination disorders and the role 
that hyperactivated mammalian target of rapamycin (mTOR) signaling plays in the 
development of these disorders, and subsequently, of epilepsy. In the second part of 
this chapter, I discuss the neurologic effects of mitochondrial and metabolic 
dysfunction and how they result in epilepsy.  
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Cortical lamination disorders, mTOR signaling, and epilepsy 
 Malformations of cortical development are one of the most common causes of 
intractable epilepsy (Blumcke et al., 2009; Aronica et al., 2012), and can be 
categorized into three groups with considerable overlap based on their causes. Group 
I consists of malformations that result from abnormal neuronal and glial proliferation 
or apoptosis, and includes conditions such as the megalencephalies, tuberous sclerosis 
complex, and the focal cortical dysplasias. Group II describes malformations resulting 
from abnormal neuronal migration, such as Pretzel Syndrome and lissencephaly. 
Finally, Group III consists of malformations from abnormal postmigrational 
development, such as the focal cortical dysplasias. A commonality among cortical 
malformation disorders is that many of them result from the dysregulation of 
signaling pathways that regulate cell size, neuronal migration, and cortical 
development. One such signaling pathway that is commonly dysregulated is the 
mammalian target of rapamycin (mTOR) signaling complex (Figure 1.2).   
 mTOR is a highly conserved, cytosolic serine/threonine kinase that is a 
member of the phosphatidylinositol-3-kinase (PI3K-related protein kinase, or PIKK) 
family (Abraham, 2004). First identified in 1991 in a genetic screen to identify the 
protein target of the drug rapamycin (Heitman et al., 1991), mTOR functions as part 
of the AMPK metabolic signaling complex to sense a cell’s nutrient, energy, and 
growth factor availability to ultimately regulate its protein expression, growth, and, in 
the nervous system, migration (Potter et al., 2001; Loewith et al., 2002; Potter et al., 
2002; Hahn-Windgassen et al., 2005; Ruvinsky et al., 2005). mTOR exists and 
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functions in two distinct multi-protein complexes, aptly named mTORC1 and 
mTORC2 (Sarbassov et al., 2004). mTORC1 is sensitive to rapamycin and regulates 
cell growth and proliferation in response to nutrient signaling and sensing. The 
majority of the literature published on mTOR is focused on mTORC1, as rictor, a 
protein component in mTORC2, is not conserved across species, rendering the study 
of mTORC2 regulators and targets less extensive and less well understood.  
Because of the role of mTOR in cell growth, proliferation, and migration, it is 
essential for the development of the brain. Knocking out mTOR in the mouse results 
in a defect in the formation of the telencephalon and embryonic lethality (Murakami 
et al., 2004). The ablation of other proteins along the mTOR pathway also results in 
embryonic or early lethality. Using nestin-Cre to create a conditional raptor knockout 
mouse to study the effects of mTOR knockout on brain development, researchers 
discovered that even the raptor conditional knockout mice died at early ages, with a 
pronounced microcephalic phenotype underscored by reductions in cell size and cell 
number (Cloëtta et al., 2013). Besides development, mTOR conditional knockout 
mice have also revealed roles for mTOR in dendrite formation (Jaworski et al., 2005) 
and axon elongation (Campbell and Holt, 2001).  
 In addition to regulating cell growth and proliferation, mTORC1 also 
regulates protein translation and ribosome biogenesis through the phosphorylation of 
ribosomal S6 kinase 1 and suppression of elongation factor 4E binding protein 1 
(4EBP1), respectively (Pause et al., 1994; Pearson et al., 1995; Saitoh et al., 2002). 
Phosphorylated S6K1 then goes on to phosphorylate the 40S ribosomal protein S6. 
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Phosphorylated S6 is a commonly used readout for mTORC1 activation, and we 
employ this readout in the studies conducted in Chapter 2. 
Recently, researchers have identified numerous genetic mutations in 
mTORC1 that underlie neurological seizure conditions. The first demonstration of an 
epilepsy syndrome directly related to enhanced mTORC1 activation was tuberous 
sclerosis complex (TSC), an autosomal dominant, multisystemic disorder resulting 
from the loss of function of one or both negative regulators of mTOR TSC1 and 
TSC2 (Baybis et al., 2004; Crino et al., 2006). TSC has been identified in all ethnic 
groups, with no gender bias. It is estimated that approximately 2 million people 
worldwide are affected with TSC, with 65-75% of patients harboring spontaneous de 
novo mutations (Hyman et al., 2000). Patients with TSC develop benign tumors in 
multiple organ systems, and brain tubers consisting of neuroglial cells exhibiting a 
loss of hexalaminar organization in the brain. Over 80% of TSC patients suffer from 
seizures, and it has been demonstrated that the cortical tubers are highly correlated 
with epileptic foci (Evans et al., 2012).  
A second example of hyperactivated mTOR signaling in seizures occurs in the 
rare, neurodevelopmental disorder polyhydramnios, megalencephaly, and 
symptomatic epilepsy syndrome (PMSE), or Pretzel Syndrome (Orlova et al., 2010). 
Pretzel Syndrome, so named because of characteristic body posture displayed by 
affected patients, results from a loss of function mutation in STE20-related kinase 
adaptor alpha (STRADA), an upstream inhibitor of mTORC1. Patients with Pretzel 
Syndrome display heterotopic neurons in the subcortical white matter and 
subependymal regions. A recent study demonstrated STRADA loss of function-
 5 
induced deficits in neuronal migration, path finding, and polarity in vitro and altered 
cortical lamination in vivo in an acute, inducible mouse model of Pretzel Syndrome, 
demonstrating another link between hyperactive mTORC1 signaling, cortical 
dyslamination, and epilepsy (Parker et al., 2013).  
 Although TSC, Pretzel Syndrome, and a number of other cortical lamination 
disorders have now been associated with identifiable mutations in mTORC1, the 
genetic cause for other mTORC1 hyperactive cortical malformation disorders remains 
elusive. One example of this is the Group I/III disorder focal cortical dysplasia type 
IIB (FCDIIB). Focal cortical dysplasia type IIB is characterized by the presence of 
balloon cells – multinucleated cells with enlarged cytoplasms – which display 
hyperactive mTOR signaling. In Chapter 2, I will discuss the discovery of a viral 
mTOR-activating agent present only in FCDIIB brain specimens that we believe 
underlies the pathogenesis of cortical dyslamination and seizures. 
 
Mitochondrial and metabolic dysfunction and epilepsy 
Mitochondrial diseases are multisystemic disorders caused by abnormal 
metabolic pathways within the mitochondria, which result in decreased energy 
production. Mitochondrial diseases can result from either an inherited gene mutation, 
or through de novo mutations in mitochondrial proteins (inborn errors of metabolism). 
There are now over 500 identified inborn errors of metabolism (Saudubray et al., 
2006), with an overall incidence 1:1000 (Campeau et al., 2008). The most common 
presentation of mitochondrial disease, inherited or congenital, is encephalomyopathy 
(Schmiedel et al., 2003), which is highly co-morbid with seizures and epilepsy. 
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Different epilepsy phenotypes have been described that result from inborn errors of 
metabolism or de novo or inherited mutations in mitochondrial DNA (most often in 
the enzymatic complexes that comprise the oxidative phosphorylation machinery) or 
mitochondria-related nuclear gene mutations (Khurana et al., 2013).  
The most well-known mitochondrial DNA-related epilepsy syndromes is 
mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS), which can result from mutations in complex I, V, or the mitochondrially 
encoded transfer RNAs histidine, leucine 1, or valine. First characterized in 1984 
(Pavlakis et al., 1984), mutations that cause MELAS often result in a build up of 
lactic acid, which results in muscle weakness, headaches, gastrointestinal issues, and 
seizures (Hirano and Pavlakis, 1994). Another mitochondrial DNA-related epilepsy 
syndrome is myoclonic epilepsy and ragged red fibers (MERRF), a condition 
resulting most often from mutations in mitochondrial transfer RNA lysine, as well as 
in leucine 1, histidine, and serine 1. Epilepsy is the defining characteristic of MERRF 
(Fukuhara et al., 1980), with patients presenting with progressive myoclonus or 
generalized tonic-clonic seizures (Berkovic et al., 1989). Lastly, Kearns-Sayre 
syndrome is a multisystemic disorder resulting from large mitochondrial DNA 
mutations that affects approximately 3 in 100,000 individuals. Mitochondrial DNA 
mutation deletions that cause Kearns-Sayre are often associated with proteins 
involved in oxidative phosphorylation. Epileptic seizures in MELAS, MERRF, and 
Kearns-Sayre syndrome can include myoclonic, tonic-clonic, absence, or status-like 
seizures, and patients frequently display more than one seizure type.  
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Though complex II is the only member of the enzymatic oxidative 
phosphorylation machinery fully encoded by nuclear DNA, the fact is nuclear DNA 
also encodes many other mitochondrial proteins, including components of the other 
oxidative phosphorylation complexes. The most common nuclear-encoded 
mitochondrial gene mutation occurs in the POLG gene, which encodes the catalytic 
subunit of the mitochondrial DNA polymerase. Mutations in POLG result in Alpers’ 
disease, a condition of severe intractable seizures occurring early in life with 
intellectual disability and hypotonia, ataxic neuropathies, and chronic progressive 
external ophthalmoplegia (Naviaux and Nguyen, 2004; Van Goethem et al., 2003; 
Van Goethem et al., 2001). Other mutations in nuclear-encoded mitochondrial 
proteins often result in the deletion of large segments of mitochondrial DNA or 
damage of mitochondrial DNA due to defective nucleotide exchange across the 
mitochondrial membrane. The encoded nuclear proteins include but are not limited to 
thymidine phosphorylase, adenine nucleotide translocator 1, and TWINKLE (Nishino 
et al., 1999; Kaukonen et al., 2000; Spelbrink et al., 2001). 
Despite the knowledge that patients with mitochondrial mutations have 
epilepsy, the cause and effect relationship between mitochondrial mutations and 
epilepsy is highly debated. On the one hand, mitochondrial dysfunction results in 
diminished ATP output and altered calcium homeostasis, both of which have effects 
on neuronal excitability and seizure susceptibility. On the other hand, prolonged 
seizures can result in mitochondrial oxidative stress and free radical production. In a 
whole genome mitochondrial DNA sequencing study of temporal lobe epilepsy 
patients, researchers found that the majority of heteroplasmic mitochondrial DNA 
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mutations was highly congregated to the epileptic region of the hippocampus, 
suggesting that mitochondrial mutations are the underlying pathology for seizures in 
temporal lobe epilepsy (Azakli et al., 2013). In Chapter 3, I will discuss the cell-
specific effects contributing to seizures of the loss of function of a nuclear-encoded 
mitochondrial protein, Slc25a12.  
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Figure 1.1. Epilepsy is a seizure disorder resulting from many different 
physiological conditions.  
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Figure 1.2. The mTOR signaling cascade.  
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Focal cortical dysplasia type IIB (FCDIIB) is a sporadic developmental 
malformation of the cerebral cortex highly associated with pediatric epilepsy. Balloon 
cells (BCs) in FCDIIB exhibit constitutive activation of the mammalian target of 
rapamycin complex 1 (mTORC1) signaling pathway. Recently, the high-risk human 
papillomavirus type 16 oncoprotein E6 was identified as a potent activator of 
mTORC1 signaling. Here, we test the hypothesis that HPV16 E6 is present in human 
FCDIIB specimens. HPV16 E6 protein was robustly expressed in all FCDIIB 
specimens in BCs, but not in regions without BCs or in control tissue specimens 
including normal brain, lymphoblasts, fibroblasts, cortical tubers, and u87 glioma 
cells. E6 expression in FCDIIB colocalized with phosphactivated S6 protein, a known 
mTORC1 substrate. HPV16 E6 DNA and mRNA were detected in representative 
specimens of FCDIIB but not control cortex, and were confirmed by sequencing. 
Transfection of E6 into fetal mouse brains caused a focal cortical malformation in 
 16 
association with enhanced mTORC1 signaling. Our results indicate a new association 
between HPV16 E6 and FCDIIB and demonstrate for the first time HPV16 E6 in the 
human brain. We propose a novel etiology for FCDIIB based on HPV16 E6 
expression during fetal brain development.  
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Introduction 
Focal cortical dysplasia type IIB (FCDIIB) is a sporadic developmental 
malformation of the cerebral cortex that is a common cause of pediatric epilepsy. 
FCDIIB is characterized by disorganized laminar architecture and enlarged, 
dysmorphic cells called balloon cells (BCs) (Blumcke et al., 2011), which exhibit 
constitutive activation of the mammalian target of rapamycin complex 1 (mTORC1) 
signaling pathway (Crino, 2011). Although aberrant mTORC1 activation can be 
caused by genetic mutations in upstream mTOR effectors, the etiology of mTORC1 
activation in BCs is unknown. We have previously proposed that FCDIIB is part of a 
pathological spectrum of developmental disorders (mTORopathies) associated with 
abnormal cortical architecture, seizures, and enhanced mTOR signaling that includes 
tuberous sclerosis complex (TSC), hemimegalencephaly, and ganglioglioma (GG) 
(Crino, 2011; Crino 2007). 
 High-risk human papillomavirus type 16 (HPV16) is the most common cause 
of cervical cancer (Faridi et al., 2011) in women and has been linked to a growing 
number of cases of oropharyngeal cancer (Bishop and Westra, 2011). Interestingly, 
the cytopathic effect of HPV16 infection on cervical epithelium results in the 
formation of koilocytes—enlarged cells with multilobulated nuclei—also called BCs 
(McLeod, 1987). The E6 oncoprotein encoded by HPV16 can be detected in clinical 
samples, and detection of HPV16 E6 DNA and mRNA by polymerase chain reaction 
(PCR), reverse transcriptase PCR (RT-PCR), or in situ hybridization (ISH) is 
considered diagnostic of HPV16 infection (Zaravinos et al., 2009). Recent work has 
shown that the HPV16 E6 oncoprotein activates mTORC1 signaling at distinct steps: 
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first by binding to TSC2 and targeting it for ubiquitin-mediated degradation (Lu et al., 
2004), and second by activating PDK1 and Akt (Spangle and Munger, 2010) 
upstream of TSC1/TSC2. In both mechanisms, mTORC1 activation is evidenced by 
enhanced phosphorylation of the ribosomal S6 protein (phospho-S6), as in cervical 
cancer (Zhou et al., 2007). We found the effects of HPV16 E6 on mTORC1 signaling 
to be strikingly similar to previous reports demonstrating reduced levels of TSC2 
(Grajkowska et al., 2008), enhanced phospho-PDK1 and phospho-Akt levels (Schick 
et al., 2007), and enhanced mTORC1 signaling in BCs (Crino, 2011) in FCDIIB. To 
date, there is no evidence that HPV16 can infect the brain, although HPV16 has been 
detected in peripheral nerves adjacent to oropharyngeal cancers (Fule et al., 2006) and 
transgenic mice expressing E6 and E7 oncoproteins develop anaplastic brain tumors 
(Arbeit et al., 1993). However, based on the cytopathic and cell signaling similarities 
between cervical dysplasia and FCDIIB, we hypothesized that HPV16 E6 DNA, 
mRNA, and protein are present in human FCDIIB brain specimens and could serve as 
a pathogenic agent in FCDIIB. We further hypothesized that expression of E6 would 
overlap with markers of mTORC1 hyperactivation and that introduction of E6 into 
fetal mouse brain would cause alteration of cortical architecture. 
 
Results 
Detection of HPV16 E6 
Antibodies recognized HPV16 E6 by immunocytochemistry in the CaSki 
HPV16 cervical cancer cell line, known to contain E6 (Figure 2.1A, B), as 
demonstrated previously (Herfs et al., 2012). In contrast, Western assay of fibroblast 
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and immortalized lymphoblastoid cell lines generated from normal control 
individuals and patients with TSC—an autosomal dominant disorder with brain 
histopathology similar to FCDIIB—did not express E6 protein, nor did U87 and 
U87vIII glioma lines (Figure 2.1C). E6 protein was not detected in normal human 
postmortem brain tissue (n=4) using 3 E6 antibodies (Figure 2.1D, E). 
In all 50 histopathologically confirmed specimens of FCDIIB (20 females, 30 
males; see Table 2.1; Supplementary Figure 2.1; Supplementary Table 2.1), there was 
robust cytoplasmic expression of E6 primarily in BCs in the subcortical white matter 
and cortical mantle that was detected by E6 ab70 and confirmed with 2 additional 
antibodies (Figure 2.2). In accordance with varying degrees of pathological 
heterogeneity in FCDIIB, subregions of some specimens did not contain BCs, and 
these regions did not exhibit E6 expression. However, regions with high BC numbers 
showed extensive E6 expression (Figure 2.1A, border zone, arrows). Similar to 
quantification of other established BC protein markers (Lamparello et al., 2007), cell 
count analyses in 10 representative FCDIIB specimens revealed that on average, 79% 
of morphologically defined BCs expressed E6 (Supplementary Figure 2.2). E6 
expression was highly specific for and exclusively linked to FCDIIB histopathology 
and was not detected in 36 control brain specimens including temporal lobe epilepsy 
specimens with no evidence of FCD (n=9), or in 5 other types of epilepsy-associated 
brain malformations including tuberous sclerosis complex (see Table 2.2; 
Supplementary Figure 2.3). “No primary’’ antibody and ubiquitous IgG1 isotype 
immunohistochemical controls did not yield an immunohistochemical reaction 
(Supplementary Figure 2.4). Interestingly, as has been demonstrated in many cervical 
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dysplasia specimens (Gatta et al., 2011) and peripheral nerve adjacent to 
oropharyngeal cancer (Fule et al., 2006), the L1 capsid protein was not detected by 
immunohistochemistry (data not shown). 
p16INK4a, a cyclin-dependent kinase inhibitor highly associated with HPV 
infection in cervical and oropharyngeal cancers (Kostopoulou et al., 2011), was 
detected immunohistochemically within BCs in all FCDIIB cases analyzed (n=20), 
but not in surrounding brain tissue without BCs (Figure 2.3) or in control brains. 
Additionally, because p53 degradation occurs in cervical cancers (Gatta et al., 2011) 
and is promoted by E6 (Doorbar, 2006; Scheffner et al., 1990), we examined p53 
expression. Contrary to previous reports (Chamberlain and Prayson, 2008), we found 
low p53 expression in astrocytes within the lesions and no expression in BCs 
(Supplementary Figure 2.5). 
 
Colocalization of E6 and Phosphoactivated mTORC1 Substrates in FCDIIB  
Next we hypothesized that E6 expression, if pathogenic through enhanced 
mTORC1 signaling, should colocalize in cells exhibiting mTORC1 activation. 
Double fluorescence immunohistochemistry was performed on FCDIIB specimens 
using antibodies against E6 and phospho-S6 (Ser235/236), a robust biomarker for 
mTORC1 activation in FCDIIB (Orlova et al., 2010). Phospho-S6 and E6 proteins 
were highly coexpressed in BCs (Figure 2.4A–C). A few cells expressing E6 did not 
exhibit phospho-S6 (see Figure 2.4D, arrow), but virtually all of the phospho-S6 
labeled cells expressed E6. In further support of our data, cortical tubers, which 
exhibit mTORC1 activation as a consequence of either mutations in TSC1 or TSC2 
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(but not E6 expression), did not exhibit E6 immunoreactivity. mTORC1 activation is 
not a feature of control brain tissue, FCDI, and MCD; this was supported by the 
absence of E6 in these tissues. 
 
HPV16 E6 DNA 
Template DNA was extracted in blinded fashion from 11 randomly selected 
FCDIIB specimens containing E6-labeled BCs and 19 control brain specimens with 
no E6 detection (see Supplementary Table 2.1). Viral cross-contamination of tissue 
blocks was unlikely, as specimens were sectioned in 3 different pathology 
laboratories. From equal quantities of template DNA, HPV16 E6-specific primers 
amplified a 477bp amplicon, confirmed by sequencing to be HPV16 E6 (homology, 
97–99%; National Center for Biotechnology Information #U34127), in all FCDIIB 
specimens but not in control brain specimens, an HPV-negative cervical cancer cell 
line, C33A, or in a no template control reaction (Figure 2.5A, top). The sequences 
amplified from our patient samples contain variations that are distinct from published 
E6 sequence (Seedorf et al., 1985), suggesting that our amplicons were distinct and 
not a uniform contaminant. As most of our sample was from individuals of Northern 
European decent, it is not surprising that we find European prototype variant E-G350 
(T350G) as the uniform isotype. As further corroboration of HPV16 infection, the 
HPV16 E7 gene, an oncogene directly adjacent to E6 in the HPV16 genome, and 
upstream long control region were also detected in FCDIIB cases by PCR 
(Supplementary Figure 2.6). 
We then show that HPV16 viral DNA can be visualized in the FCDIIB 
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specimens by ISH. FCDIIB specimens (n=7) were probed with a biotinylated HPV 
DNA probe that hybridizes robustly to HPV16 DNA in CaSki and SiHa cells 
(Montag et al., 2011), and visualized with DAB (Evans et al., 2003). HPV16 DNA 
was detected in BCs of all FCDIIB specimens, but it was not present in regions of 
FCDIIB with no BCs, or in control brain tissue (n=6, see Figure 2.5B–H and 
Supplementary Figure 2.7) (Montag et al., 2011).  
 
mRNA 
Total RNA was extracted in a blinded fashion from 12 randomly selected 
FCDIIB specimens containing E6-labeled BCs and 17 controls. RT-PCR using 
specific primer pairs designed to detect full-length HPV16 E6 and its known splice 
variants (E6*I and E6*II) detected E6 mRNA in all selected representative FCDIIB 
specimens (see Figure 2.5A, bottom) but not in any of the controls. Whereas E6 
splice variants were detected in CaSki cells, only full-length E6 transcript was 
detected in FCDIIB tissue. The detection of E6 transcript by RT-PCR provides a 
critical diagnostic link between detection of viral DNA and encoded protein and 
strongly supports the presence of HPV16 E6 in FCDIIB. 
 
HPV16 E6 Expression in Neuroglial Progenitor Cells Disrupts Cortical Lamination 
To functionally link E6 expression with the development of cortical 
malformations, we next tested the hypothesis that expression of E6 protein in 
neuroglial progenitor cells during fetal brain development disrupts cortical 
lamination. A plasmid encoding E6 was cotransfected with an RFP reporter plasmid 
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into fetal mouse brains (n=3) at embryonic day 14 (ED14) by in utero electroporation 
(Saito, 2006). Progenitor cells born on ED14 achieve a cortical laminar destination of 
layer II–III by ED19, and brains transfected with RFP plasmid alone exhibited RFP+ 
cells in layer II–III at ED19 (Figure 2.6A; Supplementary Figure 2.8). Histological 
examination of the cotransfected brains on ED19 by fluorescence microscopy 
revealed a focal cortical malformation where 74% of RFP+ cells—all of which were 
E6 immunoreactive—failed to reach their appropriate layer II–III destination and 
accumulated in the subcortical white matter and ventricular/subventricular (VZ/SVZ) 
zones (see Figure 2.6B, C). Overt cytomegaly was not observed. In cotransfected 
brains, RFP+ neurons that reached cortical layer II–III were not E6 immunoreactive 
(Figure 2.6D). Colabeling with phospho-S6 revealed that most transfected RFP+ cells 
within the focal malformation in the VZ/SVZ zones expressed phospho-S6 
(Supplementary Figure 2.9). These results demonstrate that E6 expression in neural 
progenitor cells during fetal brain development alters cortical lamination in 
association with enhanced mTORC1 activation. 
 
Conclusions and Discussion 
We demonstrate the presence of HPV16 E6 DNA, mRNA, and protein in BCs 
in FCDIIB. There was a high concordance between the localization of E6 protein and 
the phosphoactivated mTORC1 substrate S6 in BCs, suggesting a functional link 
between HPV16 E6 and mTORC1 activation in FCDIIB. Indeed, introduction of E6 
into fetal mouse brain at ED14 causes a developmental malformation of the brain, 
associated with enhanced mTORC1 signaling. Although further investigation is 
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warranted to understand how FCDIIB causes epilepsy, our findings suggest a new 
pathogenesis for FCDIIB based on localized central nervous system HPV16 infection 
during fetal brain development that accounts for many of the known features of 
FCDIIB, including sporadic occurrence, enhanced mTORC1 signaling (Crino, 2011), 
and altered brain cytoarchitecture. Our study is the first to provide an association 
between HPV16 infection and a neurological disorder and the first to detect HPV16 
in human brain. 
The standard detection methods for HPV16 in cervical dysplasia and cancer as 
well as oropharyngeal cancer include PCR, RT-PCR, ISH, and proprietary, 
commercially available capture assays. For example, the landmark paper reporting 
HPV16 in head and neck cancer detected HPV16 by PCR and ISH (Gillison et al., 
2000). Our approach included PCR, RT-PCR, ISH, and immunohistochemistry and 
thus implemented methodologies that are widely believed to represent the gold 
standards for HPV16 detection (Zaravinos et al., 2009). The E6 antibodies detected 
E6 protein in a well-described cervical cancer cell line (CaSki cells), but not in a 
variety of human lymphoblast, fibroblast, or glioma cell lines as well as normal 
control brain and several other types of brain malformation associated with epilepsy. 
We further find that pINK4a, a cell-signaling protein that is activated by E7 (also 
detected in our samples), is expressed in FCDIIB. Taken together, these data provide 
strong support for the presence of HPV16 E6 in FCDIIB. HPV16 E6 is commonly 
detected in the nucleus and cytoplasm; E6 DNA has been reported in the cytoplasm, 
nucleus, or both in cervical dysplasia (Gatta et al., 2011; Montag et al., 2011; Burns et 
al., 1987; Pillai et al., 1999) and in peripheral nerves adjacent to oropharyngeal 
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cancer (Fule et al., 2006).  
Our findings in human FCDIIB tissue are supported by expression of E6 in 
fetal mouse brain causing disruption of cortical architecture. Although BCs were not 
detected, a limitation of in utero electroporation assay is the duration of the 
transfection effect, with E6 being expressed for only 4 to 5 days (from ED14 to 
ED19). In human patients, the genesis of BCs may take much longer to occur. We 
acknowledge that a transient transfection of E6 in the mouse brain for 5 days likely 
cannot fully replicate human FCDIIB, and clearly future studies will be needed to 
examine the cellular phenotype, lineage, and excitability of the transfected cells. 
Nonetheless, our data demonstrate that expression of E6 in the fetal mouse brain leads 
to aberrant cortical lamination and supports the hypothesis that E6 may be a 
pathogenic agent in FCDIIB. 
We submit that it is highly unlikely that our results reflect artifactual 
contamination of the resected specimens or laboratory reagents. For example, the 
FCDIIB brain tissue specimens were resected under sterile surgical conditions during 
epilepsy surgery and taken immediately from the operating room to the pathology 
area in designated sterile tubes, where they were immediately fixed in formalin. HPV 
is not known to be an aerosolized virus and, for example, is not detected outside of 
areas in which gynecological procedures are performed (Strauss et al., 2002). We did 
not detect HPV16 in control specimens under blinded conditions, and HPV16 was not 
detected in a known cancer cell line (C33A) that does not contain HPV16. We did not 
detect the capsid protein L1 in our samples using immunohistochemistry; however, in 
mid to later stage cervical dysplasia, L1 is often not detected (Gatta et al., 2011). The 
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absence of L1 in FCDIIB is similar to results in peripheral nerves expressing E6 
adjacent to oropharyngeal carcinoma (Fule et al., 2006). Other genomic components 
of HPV16 such as E1 and E4 may not be detected in middle to late stage cervical 
dysplasia (Doorbar, 2006). Interestingly, severe cervical dysplasia and cervical cancer 
contain integrated HPV genomes expressing exclusively E6 and E7 rather than 
episomes capable of producing more assembled virus. 
One pivotal unresolved issue is the mode of HPV16 transmission in FCDIIB. 
Because it is believed that FCDIIB forms during embryonic brain development, a 
possibility is transplacental HPV16 infection of progenitor cells in the developing 
brain. Typically, HPV16 infects basal epithelial cells in the cervix to initiate the viral 
life-cycle and infection via putative interactions with cell surface heparan sulfate 
proteoglycans such as syndecan-1 and glypican, which are widely expressed on 
squamous epithelial cells. However, syndecan-1 is highly expressed on neural 
progenitor cells in the embryonic mouse brain (Ford-Perriss et al., 2003), thus 
providing a potential mechanism for viral entry. The transplacental HPV transmission 
rate among women with either known HPV infection, an abnormal Papanicolaou 
smear, or genital warts has been reported as 12.2% (Rombaldi et al., 2008). Thus, 
because the prevalence of HPV infection is estimated at 26.8% (Dunne et al., 2007) 
among females aged 14 to 59 years in the United States, and in many women HPV16 
infection is asymptomatic (Tota et al., 2011), transplacental spread of HPV16 is a 
plausible mechanism for entry into the brain during early fetal cortical development, 
even in the absence of overt clinical infection. Indeed, a recent study demonstrated 
that sporadic fetal brain malformations (e.g., dysplasias) could be detected as early as 
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24 weeks gestation by magnetic resonance imaging (Righini et al., 2012). 
Alternatively, it is conceivable that the effects of HPV16 E6 could lead to FCDIIB 
formation in the early neonatal period. 
Although the detection of E6 in FCDIIB provides a new insight into the 
pathogenesis of this brain malformation, the mechanism by which HPV16 might 
cause epilepsy remains to be defined. Furthermore, although we sampled a small 
number of additional brain malformation subtypes and did not detect E6, it remains 
possible that HPV16 may be pathogenic in other forms of cortical malformation. 
Clearly, future epidemiological investigation will be necessary to define the extent, 
modes, and temporal course of HPV16 transmission into the developing brain. 
 
Experimental Procedures 
Brain Specimens 
FCDIB, FCDIIA, FCDIIB, GG, mild malformation of cortical development 
(mMCD), temporal lobe epilepsy, and TSC brain tissues (Tables 2.1 and 2.2) were 
obtained following surgical resection (Academic Medical Center, Amsterdam, the 
Netherlands; University College London, London, UK, courtesy of S. Sisodiya; 
University of Pennsylvania Medical Center, Philadelphia, PA) for intractable 
epilepsy. Normal control brain tissues were obtained at postmortem examination 
(National Disease Research Interchange, Philadelphia, PA; Developmental Tissue 
Bank, University of Maryland, Baltimore, MD). Specimens were fixed in 4% 
paraformaldehyde, embedded in paraffin, and sectioned at 6 to 10 µm in 3 distinct 
pathology laboratories. All human tissue was obtained in accordance with an 
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approved institutional review board protocol. 
 
Cell Culture 
Immortalized lymphoblasts and fibroblasts derived from normal control 
individuals, and patients with known mutations in either TSC1 or TSC2, were 
obtained from Coriell (Camden, NJ). CaSki (CRL-1550) and C33A (CRM-HTB-31) 
cervical cancer cell lines were obtained from the American Type Culture Collection 
(Manassas, VA). Immortalized lymphoblasts were cultured in RPMI-1640 media 
(Invitrogen, Grand Island, NY), 15% fetal bovine serum (FBS), 2mM L-glutamine. 
Immortalized fibroblasts were cultured in modified Eagle medium (MEM; Invitrogen, 
Grand Island, NY) supplemented with 15% FBS and 2 mM L-glutamine. U87 glioma 
cells were obtained courtesy of D. O’Rourke, Perelman School of Medicine and were 
cultured in Dulbecco MEM supplemented with 1% FBS and 1% 
penicillin/streptomycin. CaSki cells were cultured in RPMI-1640 media (Invitrogen) 
supplemented with 10% FBS and 1% penicillin/streptomycin. C33A cells were 
cultured in MEM supplemented with 10% FBS. 
 
Immunohistochemistry 
Brain sections were probed with antibodies recognizing E6 (ab70, Abcam, 
Cambridge, MA; MA1-46057, Thermo Scientific, Waltham, MA; sc-1583, Santa 
Cruz Biotechnology, Santa Cruz, CA), phospho-S6 (108D2; Cell Signaling 
Technology, Danvers, MA), p16INK4a (ab54210, Abcam), or p53 (ab26, Abcam) 
overnight at 4 degrees in TRIS buffer pH 7.4/2% fetal bovine serum), incubated in 
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biotinylated secondary antibody, and visualized using avidin–biotin conjugation 
(Vectastain ABC Elite, Vector Laboratories, Burlingame, CA or Powervision Kit, 
Immunologic, Duiven, the Netherlands) with 3,3’-diaminobenzidine under light 
microscopy. For double-labeling studies, after incubation with primary antibodies, 
sections were incubated for 2 hours with Alexa Fluor 568 and Alexa Fluor 488 
(antirabbit immunoglobulin G [IgG] or antimouse IgG; 1:200; Molecular Probes, 
Eugene, OR) and visualized with a laser scanning confocal microscope (SP2, argon-
ion laser; Leica, Wetzlar, Germany). All immunostained sections were assessed in a 
blinded fashion independently by 2 observers. 
 
PCR 
DNA was extracted from FCDIIB specimens exhibiting E6 expression (see 
Results) and from control sections without evidence of E6 expression (QIAamp DNA 
FFPE Tissue Kit; QIA- GEN, Valencia, CA). Equal amounts of template genomic 
DNA were used for PCR in designated PCR-safe, contaminant-free stations. Primers 
amplifying the entire HPV16 E6 coding regions (5’-
ATGCACCCAAAGAGAACTGCA-3’ forward; 5’-
ATTACAGCTGGGTTTCTCTACG-3’ reverse) were used to detect viral genomic 
DNA brain specimens. DNA was subjected to 35 cycles of PCR amplification. 
Amplicons were resolved on a 1.5% agarose gel and were sequenced at the PENN 
Sequencing Facility. 
 
In Situ Hybridization 
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Detection of HPV DNA in situ in resected tissue sections was accomplished 
using GenPoint HPV Biotinylated DNA Probe recognizing genomic clones of several 
HPV isotypes, including HPV16 and 18, that account for >90% of cervical cancers 
(Dako, Carpinteria, CA) and GenPoint Tyramide Signal Amplification System for 
Biotinylated Probes (Dako). In situ hybridization was achieved as previously 
described15 with the addition of 200 µg/ml proteinase K in water and 1:50 
diaminobenzidine (DAB) for 5 minutes, and visualized under light microscopy. 
Assessment of the sections was performed in a blinded fashion by 2 investigators. 
  
RT-PCR 
RNA was extracted from tissue sections (RNeasy FFPE Kit; QIAGEN). 
Synthesis of cDNA and RT-PCR were performed (OneStep RT-PCR Kit; QIAGEN). 
RT-PCR primers amplifying full-length HPV16 E6 cDNA and known splice variants 
E6*I and E6*II were used (5’-AATGTTTCAGGACCCAC AGG-3’ forward; 5’-
CAGCTGGGTTTCTCTACGTGTTC-3’ reverse). RNA was subjected to 40 rounds 
of PCR amplification after cDNA synthesis. Amplicons were resolved on a 1.5% 
agarose gel and were sequenced at the PENN Sequencing Facility. 
 
In Utero Electroporation 
Introduction of plasmid cDNAs by in utero electroporation into fetal C5BL/6 
mice (Charles River, Wilmington, MA) on embryonic day (ED) 14 was achieved as 
reported previously.16 E6 (plasmid 8641; Addgene, Cambridge, MA) and red 
fluorescent protein (RFP) plasmids (5 µl each) were microinjected into the lateral 
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ventricle of fetal mouse brains (n=3). In control mice, an RFP-only plasmid was 
injected (n=5). Following microinjection, the lateral aspects of the brain were 
exposed to a brief electrical field pulse (40V) by a forceps-type electrode 
(CUY21EDIT Square Wave Electroporator; Sonidel, Dublin, Ireland) to effect 
passage of the plasmid into cells. Embryos were euthanized at ED19. Brains were 
flash frozen on dry ice, and 10 µm sections were probed with E6 and phospho-S6 
antibodies. Sections were visualized by fluorescence (DM4000 B microscope, Leica) 
or confocal (LSM510; Zeiss, Thornwood, NY) microscopy. Animal experiments were 
performed in accordance with an approved institutional animal care and use 
committee protocol. 
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Figure 2.1. E6 is detected in CaSki cervical cancer cells. 
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Figure 2.1. E6 is detected in CaSki cervical cancer cells. 
A) With ab70 antibody 
B) With sc-1583 antibody. Cytoplasmic staining can be seen as well. Scale bar = 50 
µm. 
C) Western assay depicting absence of E6 protein expression in immortalized 
lymphoblasts and cultured fibroblasts from normal control individuals and 
patients with tuberous sclerosis complex (TSC), as well as U87 glioma cell lines. 
Protein loading was confirmed with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). GBM indicates glioblastoma multiforme. 
D) Absence of E6 expression in control brain specimens. 
E) Absence of E6 expression in control brain specimens. 
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Figure 2.2. E6 immunoreactivity in 6 distinct focal cortical dysplasia type IIB 
specimens. 
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Figure 2.2. E6 immunoreactivity in 6 distinct focal cortical dysplasia type IIB 
specimens. 
A) E6 expression in balloon cells, but not overlying cortex (border zone, arrows). 
Scale bar = 250 µm. 
B) E6 expression in balloon cells. Scale bar = 100 µm. 
C) E6 detected and visualized with high magnification. Scale bar = 75 µm. 
D) E6 detected and visualized with high magnification. Scale bar = 75 µm. 
E) E6 detected and visualized with high magnification. Scale bar = 100 µm. 
F) E6 detected and visualized with high magnification. Scale bar = 75 µm. 
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Figure 2.3. p16INK4a immunoreactivity in focal cortical dysplasia type IIB 
(FCDIIB) balloon cells (BCs).  
 
 
 
 
 
 
 
 37 
Figure 2.3. p16INK4a immunoreactivity in focal cortical dysplasia type IIB 
(FCDIIB) balloon cells (BCs).  
A) Phase contrast light microscopy depicting absent p16INK4a immunoreactivity in 
control cerebral cortex. Neurons in A can be seen without p16INK4a labeling 
(arrows). Scale bar = 100 µm. 
B) p16INK4a immunoreactivity in FCDIIB BCs. Scale bar = 100 µm. 
C) p16INK4a in nucleus of BC (arrow). Scale bar = 200 µm.  
D) Minimal p16INK4a expression in cortex surrounding FCDIIB with no BCs. Scale 
bar = 100 µm. 
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Figure 2.4. Coexpression of E6 and phosphorylated S6 proteins in focal cortical 
dysplasia type IIB (FCDIIB). 
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Figure 2.4. Coexpression of E6 and phosphorylated S6 proteins in focal cortical 
dysplasia type IIB (FCDIIB). 
A) Balloon cells in FCDIIB express both E6 (green) and phosphor-S6 (red) proteins 
(arrows). DAPI nuclear stain is shown in blue. Scale bar = 25 µm. 
B) Balloon cells in FCDIIB express both E6 (green) and phosphor-S6 (red) proteins 
(arrows). DAPI nuclear stain is shown in blue. Scale bar = 25 µm. 
C) Balloon cells in FCDIIB express both E6 (green) and phosphor-S6 (red) proteins 
(arrows). DAPI nuclear stain is shown in blue. Scale bar = 25 µm. 
D) Rare cells express E6 only within minimal phosphor-S6 colabeling (arrow). Scale 
bar = 25 µm.  
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Figure 2.5. E6 DNA and mRNA detection in focal cortical dysplasia type IIB 
(FCDIIB) specimens by polymerase chain reaction (PCR), reverse transcriptase 
PCR (RT-PCR), and in situ hybridization.  
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Figure 2.5. E6 DNA and mRNA detection in focal cortical dysplasia type IIB 
(FCDIIB) specimens by polymerase chain reaction (PCR), reverse transcriptase 
PCR (RT-PCR), and in situ hybridization.  
A) E6 DNA and mRNA are detected by PCR and RT-PCR in CaSki cells (lower 
molecular weight bands in RT-PCR represent E6 splice variants) and 8 different 
representative FCDIIB specimens, but not in control brain, C33A cells, or no 
template control. 
B) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells. 
Scale bar = 125 µm. 
C) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells. 
Scale bar = 80 µm. 
D) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells. 
Scale bar = 80 µm. 
E) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells. 
Scale bar = 125 µm. 
F) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells. 
Scale bar = 80 µm. 
G) E6 detection by in situ hybridization in nuclei and cytoplasm of balloon cells. 
Scale bar = 125 µm. 
H) Absent hybridization signal in control cortex. Pial surface is depicted by arrow. 
Scale bar = 125 µm.  
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Figure 2.6. E6 transfection in utero causes a focal cortical malformation. 
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Figure 2.6. E6 transfection in utero causes a focal cortical malformation. 
A) Red fluorescent protein (RFP)+ cells achieve appropriate laminar destination 
(layer II/III) following in utero electroporation with RFP plasmid alone (see also 
Supplementary Figure 2.8). Scale bar = 100 µm. 
B) Focal cortical malformation at embryonic day 19 following in utero 
electroporation of E6 and RFP plasmids (arrows). Scale bar = 100 µm. 
C) Cells retained within the ventricular/subventricular zones coexpress RFP and E6 
(inset, higher magnification). Scale bar = 100 µm. 
D) In cotransfected brains, cells reaching the cortical plate do not express E6. In 
bottom panel, confocal microscopy demonstrating cellular colocalization of E6 
and RFP within the focal malformation depicted in C. Scale bar = 100 µm. 
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Table 2.1. HPV E6 protein is detected in 50 FCDIIB specimens.  
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Table 2.2. Absence of E6 in non-FCDIIB cases.  
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Supplemental Figure 2.1. FCDIIB specimens exhibiting nestin (a-b) and vimentin 
(c) immunoreactivity. Note that most BCs exhibit robust nestin and vimentin 
expression. Scale bar: 150 µm (a,c); 100 µm (b). 
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Supplemental Figure 2.2. Percentage of BCs that express E6. Morphologically 
dlefined BCs from 10 representative cases were examined at high magnification (40x) 
for total BC counts. E6 expression in each BC was determined as present or absent 
and the percentage of morphologically identified BCs that expressed E6 protein was 
calculated.  
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Supplemental Figure 2.3. Absent E6 immunoreactivity in human TSC speciments. 
Cortical tubers (a-c), subependymal giant cell astrocytoma (d). Scale bar: 150 µm (a, 
c), 100 µm (b, d). 
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Supplemental Figure 2.4. Immunohistochemistry control experiments. No primary 
(E6) antibody controls (a-b). Isotype IgG antibody with no primary (E6) added (c-d). 
Note absence of immunolabeling in balloon cells (arrows). Scale bar = 150 µm. 
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Supplemental Figure 2.5. p53 expression in FCDIIB. p53 immunoreactive 
astrocytes in FCDIIB specimens (a). Absence of p53 immunoreactivity in BCs (b, 
arrow). Scale bar: 200 µm.  
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Supplemental Figure 2.6. PCR in representative FCDIIB cases for HPV16 E7 and 
HPV16 LCR revealed 297bp and 439bp amplicons. DNA sequencing confirmed the 
identity of viral elements and BLAST against HPV16 E7 and LCR sequence revealed 
98% sequence similarity. 
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Supplemental Figure 2.7. HPV DNA is not present in control brain (a) and regions 
of FCDIIB specimens with no balloon cells (b-c) by in situ hybridization. Note single 
neuron (b; arrow). Small arrows in a and c depict the pial surface.  
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Supplemental Figure 2.8. In utero electroporation of RFP plasmid does not disrupt 
normal cortical lamination. Transfection of RFP plasmid on embryonic day 14 by in 
utero electroporation labels a population of cells destined for layer II-III (a). Co-
labeling with Cux1 antibody reveals normal expression of Cux1 protein in transfected 
layer II-III cells (b). Hoechst labeling demonstrates laminar organization of the cortex 
(c). Composite photomicrograph showing direct overlay of RFP and Cux1 in layer II-
III (d). Scale: 100 µm.  
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Supplemental Figure 2.9. Three dimensional confocal microscopy demonstrates co-
localization of RFP and phosphor-S6 (P-S6) protein in cells within the subventricuar 
zone following electroporation with RFP and E6 plasmids. Three RFP transfected 
cells are shown. The cells at right and left exhibit P-S6 immunoreactivity (green), 
shown in overlay on far right; the center cell does not show phosphor-S6 labeling. 
Cross sectional image for this cell is depicted in left panels (L); apical view of both 
cells represented in top panels (T).  
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Supplemental Table 2.1. Table detailing detection assays conducted on FCDIIB or 
control cases. Check mark denotes assay was performed.  
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Chapter 3 
Astrocytic apoptosis and contributions to seizures in 
Slc25a12 mutant mice 
 
Slc25a12 is a mitochondrial aspartate-glutamate carrier that promotes the 
effective crossing of reducing equivalents into the mitochondria, which are then used 
as electron donors for the electron transport chain. Patients with Slc25a12 loss of 
function mutations develop autism-like neurological abnormalities and seizures early 
in life. In this study, we employ knock out (KO) mouse technology to study the effect 
of complete Slc25a12 KO on different neural cell types. We show that Slc25a12 KO 
hippocampal astrocytes undergo apoptosis, down-regulate their expression of 
glutamate reuptake transporters, and up-regulate the neuromodulatory protein 
adenosine kinase, all of which may contribute to the dysregulation of glutamatergic 
neurotransmission. Our data uncover an unexpected role for astrocytes in seizure 
genesis and continue to underscore the importance of studying the most abundant and 
underappreciated neural cell type to probe its contributions to seizures and other 
neurological disorders, as well as its potential for therapeutic interventions.  
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Introduction 
The mitochondrial aspartate-glutamate carrier isoform 1, also known as aralar, 
or Slc25a12, is a calcium-binding protein localized to the inner mitochondrial 
membrane. As part of the malate-aspartate shuttle, it transfers reducing equivalents in 
the form of NADH from the cytosol to the mitochondria by catalyzing the exchange 
of intermitochondrial aspartate and cytosolic glutamate and a proton (Figure 3.1). 
Discovered and cloned in 1998 (del Arco and Satrústegui, 1998), Slc25a12 was later 
identified as an autism susceptibility gene after multiple genome wide association 
studies found Slc25a12 SNPs highly associated with autism spectrum disorders 
(Ramoz et al., 2004; Segurado et al., 2005; Silverman et al., 2008; Turunen et al., 
2008; Chien et al., 2010; Kim et al., 2011; Anitha et al., 2012; Li et al., 2012; 
Prandini et al., 2012). Though the link between Slc25a12 and autism has been 
contested by a few (Blasi et al., 2006; Correia et al., 2006; Rabionet et al., 2006; 
Lepagnol-Bestel et al., 2008), two recent meta-analysis studies further substantiated 
the association (Aoki and Cortese, 2015; Liu et al., 2015). Recently, two independent 
case studies identified three patients with loss of function mutations in Slc25a12 
(Wibom et al., 2009; Falk et al., 2014). These patients develop normally during the 
first few months of life after which they begin to develop psychomotor deficits and 
seizures. It is not currently known what changes in the brain resulting from Slc25a12 
loss of function lead to seizures. Here, we use Slc25a12 KO mice to investigate the 
effect of Slc25a12 loss of function on different neural cell types to examine their role 
in seizure genesis.  
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 The pathogenesis of astrocytes is increasingly being recognized as a major 
contributor to many neurological disorders. In seizure disorders, a number of 
astrocyte-specific deficiencies have now been identified in both human temporal lobe 
and animal models of epilepsy that contribute to seizure propensity (Bordey and 
Sontheimer, 1998; Das et al., 2012). The most well established astrocyte abnormality 
documented in seizure disorders is reactive astrocytosis, whereby astrocytes display 
hypertrophic morphology and increased expression of astrocytic intermediate 
filaments GFAP and vimentin. Other astrocyte deficiencies include changes in ion 
channel composition (Kir4.1) reflecting an inability of astrocytes to buffer 
extracellular potassium (Wallraff et al., 2006; Sicca et al., 2011); reduction in 
glutamate transporters (GLT-1, GLAST) (Mathern et al., 1999; Proper et al., 2012; 
Sarac et al., 2009; Takahashi et al., 2010) and glutamate degrading enzymes such as 
glutamine synthetase (Dennis et al., 1977; Eid et al., 2004; van der Hel et al., 2005), 
resulting in the inability to sequester and degrade synaptic glutamate into the 
astrocytic cytosol; and disrupted homeostasis of neurotransmitter precursors for both 
excitatory and inhibitory neurotransmission . In this study, we report a novel 
astrocytic deficiency that we believe may further contribute to the pathophysiology 
and exacerbation of seizures in Slc25a12 KO mice.  
 
Results 
Slc25a12 is expressed in neurons, interneurons, and astrocytes 
Slc25a12 mRNA is expressed in pyramidal neurons in mouse cortex and 
hippocampus (del Arco et al., 2002; Ramos et al., 2003), prompting us to examine 
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whether the regional localization of its protein expression follows suit. We probed 
brain tissue from wild type mouse brain using antibodies recognizing Slc25a12. We 
found that Slc25a12 protein was highly expressed in cortical pyramidal neurons 
(Figure 3.2A), similar to mRNA in situ hybridization expression patterns. Here, we 
also demonstrated the specificity of the Slc25a12 antibody by using it on Slc25a12 
KO brain tissue, where Slc25a12 protein is clearly not detected (Figure 3.2A). To 
determine whether Slc25a12 is expressed in inhibitory interneurons, we examined 
wild type mouse brain tissues using antibodies against parvalbumin (PV), the 
calcium-binding protein expressed in a subset of fast-spiking interneurons. Consistent 
with the high numbers of mitochondria in PV interneurons (Gulyás et al., 2006), we 
found that Slc25a12 protein was also detected in this cell type (Figure 3.2B).  
 The astrocytic expression of Slc25a12 has not been established and is highly 
debated. Some groups found that astrocytes do not express Slc25a12 protein (Ramos 
et al., 2003; Pardo et al., 2011), while others argued that astrocytes are metabolically 
compromised without Slc25a12, and demonstrated using the rigorous methodology of 
electron microscopy with immunogold labeling, that astrocytes do in fact express 
Slc25a12 (Li et al., 2012). Using a GLT-1-GFP transgenic BAC mouse, which 
expresses GFP in all astrocytes from P10 to adulthood (Regan et al., 2007), we found 
prominent Slc25a12 expression in astrocytes of both the cortex and the hippocampus 
(Figure 3.2C). This implies that Slc25a12 loss of function may have more diverse 
effects than previously realized, given the intermediary roles that astrocytes have, 
particularly in glutamatergic neurotransmission. 
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Loss of Slc25a12 does not adversely impact interneuron development and 
differentiation 
Abnormal GABAergic signaling is known to underlie some seizure disorders, 
as evidenced by genetic mutations in interneuron development that lead to seizure 
states (McManus and Golden, 2005; Friocourt et al., 2008; Cobos et al., 2005). 
Interestingly, mitochondrial disease is also starting to gain recognition as a major 
contributor to seizures and epilepsy, as the incidence of seizures in patients with 
mitochondrial disease is greater than that of the general population and the fact that 
there is an increasing number of identified mitochondrial mutations that result in 
epilepsy (Khurana et al., 2008; Kang et al., 2013). Preliminary data from our lab has 
shown that interneurons rely on mitochondrial oxidative phosphorylation for 
tangential migration to the cortex (Lin-Hendel et al., unpublished), further 
substantiating, and establishing a precedent for the dual role that interneurons and 
mitochondria play in seizure disorders. This led us to investigate whether loss of 
Slc25a12 would result in a deficit in interneuron development.  
 We examined GABAergic interneuron numbers in wild type and Slc25a12 
KO mice by probing tissues with an antibody against GABA. We focused our 
analysis on the hippocampus, since it is known to be a highly epileptogenic region, 
and it was previously demonstrated that loss of interneurons in the hippocampus led 
to a seizure-like state (Sloviter, 1987; de Lanerolle et al., 1989; Dudek, 2002; Cobos 
et al., 2005). To our surprise, the number of GABAergic interneurons in Slc25a12 
KO hippocampus did not significantly differ from wild type (Figure 3.3A).  
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 To investigate whether Slc25a12 KO affected interneuron differentiation, we 
induced interneuron differentiation on induced pluripotent stem cells (iPSCs) derived 
from patients with partial Slc25a12 loss of function (Falk et al., 2014). The 
differentiation protocol has been used in our lab to successfully differentiate iPSCs 
into interneurons (Maroof et al., 2013) and consists of exposing iPSCs to a variety of 
small molecules to first enhance forebrain differentiation and then achieve cell type 
ventralization, mimicking the environment of the medial ganglionic eminence where 
interneurons are naturally born (Figure 3.3B). After subjecting patient-derived iPSCs 
to this differentiation protocol, we showed that Slc25a12 loss of function iPSCs were 
able to successfully differentiate into cells that expressed Nkx2.1, a transcription 
factor critical for the determination and specification of inhibitory interneurons 
(Figure 3.3C), suggesting that Slc25a12 loss of function does not affect the initial 
development of GABAergic interneurons.  
 Though the investigation of interneuron numbers and differentiation does not 
shed light on the effect of Slc25a12 KO on interneuron function, it suggests that 
Slc25a12 is not required for interneuron migration and that insufficient interneuron 
numbers is most likely not the cause of seizures in Slc25a12 KO mice/patients.  
 
Slc25a12 KO results in hippocampal selective astrocyte apoptosis with compensatory 
increase in astrocyte numbers 
 Despite the respiratory chain being functionally intact, patients with loss of 
function mutations in Slc25a12 have reduced ATP output (Wibom et al., 2009), most 
likely due to a reduction in reducing equivalents (used to fuel ATP synthesis) being 
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imported into the mitochondria by Slc25a12’s actions as part of the malate aspartate 
shuttle. Cells that undergo metabolic stress and do not produce enough ATP can 
undergo apoptosis (Aito et al., 2002; Altman and Rathmell, 2012). The brain is one of 
the most energy-consuming organs in the body, using up to 20% of the body’s basal 
metabolism despite being only 2% of the total body weight (Raichle and Gusnard, 
2002). We reasoned that the high-energy demands of the brain would make it 
particularly susceptible to reduced ATP output, leading to cellular apoptosis across 
the board. To test this idea, we examined wild type and Slc25a12 KO brains with the 
apoptotic marker cleaved caspase 3.  
 To our surprise, we observed an astounding region-specific enrichment of 
cleaved caspase 3-expressing cells in the hippocampus of Slc25a12 KO mice (Figure 
3.4A). Using double labeling with the astrocytic marker S100β, we also determined 
that the apoptosis was specific to astrocytes, with over 50% of S100β-expressing 
astrocytes also expressing apoptotic markers (Figure 3.4B). The statistical variance 
observed may be due to the small number of animals tested, but quite possibly also 
the heterogeneity in the developmental progression of the phenotype. This 
heterogeneity is also observed in the patients with loss of function Slc25a12 
mutations, where the onset of seizures varies from 7-10 months. Though we observed 
apoptosis in all hippocampal CA fields, the phenotype was most pronounced and 
statistically significant in the hilus, and we confirmed this result using other apoptotic 
markers cleaved PARP and the TUNEL assay (Figure 3.4C).  
 In mouse, most astrocytes in the hippocampus are generated by P16 (Nixdorf-
Bergweiler et al., 1994). Since astrocyte apoptosis is most pronounced at P16 in 
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Slc25a12 KO hippocampus, we wondered whether the putative loss of astrocytes to 
apoptosis in Slc25a12 KO hippocampus would lead to a compensatory increase in 
astrocytes. To test this question, we examined whether an increase in both immature 
and mature astrocytes would be apparent in Slc25a12 KO hippocampus. In wild type 
hippocampus, the immature astrocyte marker CD44 is expressed at low levels from 
P5-P7 and diminishes at P11, consistent with the developmental timeline of astrocyte 
proliferation (Bushong et al., 2004). In Slc25a12 KO hippocampus, CD44 was 
enriched from P5-P7, and particularly at P11 (Figure 3.5A), indicating either that 
astrocyte maturation is delayed, or that astrocytes proliferate to replenish apoptosing 
astrocytes. An analysis of total astrocyte numbers in Slc25a12 KO hippocampus at 
P16 indicates that there are significantly more astrocytes compared to wild type, 
suggesting that astrocyte proliferation may in fact be compensating for apoptotic cell 
loss (Figure 3.5B).  
 
Hippocampal astrocyte apoptosis is not apparent in mice deficient in the 
transcription factor Arx  
 It had been previously demonstrated that kainic acid-induced status 
epilepticus resulted in robust cleaved caspase 3 expression in astrocytes (Narkilahti et 
al., 2003), suggestive of apoptosis. However, evidence for this occurring in a genetic 
seizure model other than Slc25a12 KO has been lacking. To determine whether 
astrocyte apoptosis could also result from non-chemically-induced persistent seizures, 
we examined Arx null mice for evidence of astrocyte apoptosis.  
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Arx is one of several homeodomain-containing transcription factors involved 
in GABAergic interneuron migration and maturation in the brain (McManus and 
Golden, 2005; Friocourt et al., 2008). Similar to patients with Slc25a12 loss of 
function mutations, patients with mutations in Arx exhibit spontaneous persistent 
seizures with developmental delay. Using mice with a GCG triplet repeat expansion 
in Arx (Arx(GCG)10+7), which are viable and recapitulates the features of the human 
triplet repeat expansion (Price et al., 2009), we observed that astrocyte apoptosis was 
not apparent before or after the age of seizure onset (~P30) (Figure 3.6), suggesting 
that the phenotype is unique to Slc25a12 KO. 
 
Hippocampal astrocyte apoptosis precedes onset of behavioral seizures 
 In many epilepsy models as well as in human epilepsy, prolonged seizures can 
result in neuronal cell death in the hippocampus (Zhang et al., 1998; Faherty et al., 
1999; Henshall et al., 2004; Henshall 2007). In one study, kainic acid-induced status 
epilepticus also resulted in pronounced hippocampal astrocytic cell death (Narkilahti 
et al., 2003). To determine whether astrocyte cell death in Slc25a12 KO mice 
precedes seizures or is a result of them, we used video seizure monitoring to examine 
whether the onset of behavioral seizures precedes or follows the onset of astrocyte 
apoptosis at P11.  
While behavioral seizures in Slc25a12 KO mice are entirely spontaneous, we 
found that a one-hour period of monitoring from ages P7-P16 was sufficient to 
document a spontaneous seizure. In this time period, 6 of 7 Slc25a12 KO mice 
exhibited behavioral seizures by P15, with the earliest occurring on P13, two days 
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after the onset of astrocyte apoptosis (Figure 3.5C). Unlike the kainic acid-induced 
seizure model where seizures resulted in astrocyte apoptosis, that astrocyte apoptosis 
in Slc25a12 KO precedes the onset of behavioral seizures suggests that astrocytes 
may contribute to seizure genesis.  
 
Slc25a12 KO astrocytes down-regulate expression of glutamate transporters GLT-1 
and GLAST 
 Astrocytes play an important role in the modulation of excitatory 
neurotransmission. They achieve this in part through the expression of the sodium-
dependent glutamate reuptake transporters GLT-1 and GLAST, which clear glutamate 
from the synaptic cleft, thereby ceasing its effects on postsynaptic glutamate 
receptors. Our evidence refuting the notion that interneurons may be a driver of 
seizure genesis in Slc25a12 KO mice prompted us to examine whether Slc25a12 KO 
astrocytes exhibit other abnormalities that would contribute to seizures. Previous 
studies have shown that GLT-1 and GLAST protein expression is down-regulated in 
other seizure models (Miller et al., 1997; Tanaka et al., 1997; Dutuit et al., 2002; 
Zhang et al., 2004). To test this idea, we examined hippocampal glutamate levels and 
GLT-1 and GLAST protein expression from wild type and Slc25a12 KO mice. 
 Our findings indicate that the expression of astrocytic glutamate reuptake 
transporter GLT-1 is significantly decreased in the Slc25a12 KO hippocampus 
(Figure 3.7). 5-10% of GLT-1 protein is also expressed in neurons. We maintain that 
the loss of GLT-1 in Slc25a12 occurs in astrocytes, as a preliminary analysis of 
glutamate reuptake in P2 synaptosomes revealed that glutamate reuptake was not 
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different between Slc25a12 KO and wild type, an effect that can be explained by the 
recent finding that neuronal GLT-1 is the major contributor to glutamate uptake in P2 
synaptosomes (Petr et al., 2015). Hippocampal GLAST was also shown to have a 
decreasing trend (Figure 3.7). The lack of glutamate reuptake transporters in 
Slc25a12 KO suggests a role for altered glutamate neurotransmission in seizure 
genesis. 
 
Electrophysiology of Slc25a12 KO pyramidal cells indicate evidence of synaptic 
glutamate retention  
 We examined amplitude, frequency, area, and decay of mEPSPs in 
hippocampal CA3 excitatory pyramidal cells in wild type and Slc25a12 KO mice. We 
found the amplitude unchanged, suggesting that the amount of glutamate packaged 
and released by the pyramidal cells is not different between KO and wild types 
(Figure 3.8A). In addition to this, we found that there were more frequent glutamate 
release events in the KO, as evidenced by the leftward shift in the cumulative 
probability of Slc25a12 KO events, or the decrease in Slc25a12 KO inter-event 
interval (Figure 3.8B). This finding, coupled with the enhanced area under the 
mEPSP curve (Figure 3.8C) and longer delay towards signal decay (Figure 3.8D) in 
Slc25a12 KO animals supports the hypothesis that Slc25a12 KO animals have 
prolonged synaptic glutamate retention that may contribute to seizures. These 
electrophysiological data support the biochemical GLT-1 expression data. The 
glutamate reuptake transporters contribute directly to the amplitude of the mEPSPs by 
virtue of their kinetics. Glutamate reuptake transporter kinetics are known to be 
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considerably faster than the kinetics of post-synaptic glutamate receptors, and thus, 
their absence or down-regulation will cause an enhancement of the mEPSP 
amplitude. To determine how GABAergic neurotransmission is altered, we have 
measured mIPSPs; the analysis is forthcoming.  
 
Slc25a12 KO astrocytes up-regulate expression of the neuromodulatory kinase ADK 
 Adenosine has been identified as an inhibitory neuromodulator through its 
effects on reducing glutamate release (Corradetti et al., 1984). Adenosine-modulated 
inhibitory tone can be disturbed, resulting in seizure states, through its 
phosphorylation into AMP by ADK. ADK exists in a long and short isoform, found in 
the nucleus and cytoplasm, respectively (Cui et al., 2009). In early postnatal 
development, ADK-L is expressed specifically in neuronal nuclei, and for reasons 
unknown, the ADK shifts its isoform and cellular expression to astrocytic ADK-S by 
P14 (Studer et al., 2006). Research from Detlev Boison’s group has shown that ADK-
S is up-regulated in hippocampal astrocytes in human temporal lobe epilepsy, and 
becomes up-regulated as a result of reactive astrocytosis in animal models of epilepsy 
(Gouder et al., 2004; Fedele et al., 2005; Li et al., 2008; Shen et al., 2014). Moreover, 
overexpressing ADK-S in a kainic acid model of epilepsy exacerbated seizures, 
suggesting that up-regulated ADK may play a role not only in genesis, but also in 
perseverance of seizures (Fedele et al., 2005). This prompted us to examine whether 
ADK was up-regulated in Slc25a12 KO mice, and whether seizures resulted from 
ADK-driven loss of inhibitory tone.  
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Our immunohistological examination of ADK revealed enhanced astrocytic 
ADK in Slc25a12 KO hippocampus (Figure 3.9A). However, unlike previously 
published reports on ADK expression levels in seizure models, we found that total 
ADK protein levels were unchanged between wild type and Slc25a12 KO (Figure 
3.9B). Upon further examination, we observed that ADK in Slc25a12 KO astrocytes 
was localized to the nucleus. It is not known how ADK functions in the nucleus, and 
whether it affects the bioavailability of adenosine like cytoplasmic ADK. However, 
the aberrant localization of ADK in Slc25a12 KO astrocytes contributes to growing 
evidence of astrocytic abnormalities that may contribute to altered glutamate 
neurotransmission and seizure states.  
 
Discussion 
In this study, we identify a novel phenotype – hippocampal-specific astrocyte 
apoptosis occurring before the onset of behavioral seizures – that strongly implicates 
the astrocyte as a major contributor to seizure genesis in Slc25a12 KO mice. We 
further confirm the role of astrocytes in Slc25a12 KO seizure genesis by showing that 
astrocytes also down-regulate their expression of glutamate reuptake transporters 
GLT-1 and GLAST, and up-regulate the expression of ADK, resulting in glutamate 
excitotoxicity through glutamate retention in the synaptic cleft and an increase in 
glutamate release events, respectively. These effects are supported by the 
electrophysiological characteristics of hippocampal pyramidal cells.  
 
Normal interneuron development in Slc25a12 KO mice  
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 Mitochondrial ATP via oxidative phosphorylation is required for interneuron 
tangential migration (Lin-Hendel et al., unpublished), and interneurons, particularly 
the fast-spiking subset, contain large amounts of mitochondria (Gulyás et al., 2006). 
How might knocking out Slc25a12, a mitochondrial protein indirectly involved in 
ATP generation, lead to the normal development of interneurons? Postnatal 
expression of Slc25a12 is limited to only a few organs: the brain, heart, and skeletal 
muscle (del Arco et al., 2002). During development, Slc25a12 shares overlapping 
expression with its protein isoform Slc25a13, particularly in the brain (del Arco et al., 
2002). This overlapping expression persists until the end of neurogenesis and 
interneuron migration, and suggests that Slc25a13 may provide functional 
compensation for neural development in Slc25a12 KO mice, leading to normal 
interneuron development.  
 
Astrocyte apoptosis: Cell autonomy  
 Oligodendrocytes do not express Slc25a12, yet both Slc25a12 loss of function 
patients and Slc25a12 KO mice exhibit global central nervous system 
hypomyelination (Jalil et al., 2005; Wibom et al., 2009; Sakurai et al., 2009; Falk et 
al., 2014), a non-cell autonomous phenotype that was demonstrated to be a result of a 
lack of neuron-supplied N-acetylaspartate, which oligodendrocytes use to synthesize 
myelin. The astrocytic expression of Slc25a12 has been a subject of debate. We have 
shown that Slc25a12 is expressed in astrocytes, suggesting that global Slc25a12 KO 
may contribute to cell autonomous effects in astrocytes, though this does not rule out 
non-cell autonomous effects neuronal Slc25a12 KO may have on astrocytes.  
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 One method we plan to use to determine cell autonomy is an in vitro system 
where neurons and astrocytes that are either both wild type, both Slc25a12 KO, or of 
mixed genotypes are co-cultured. These cultures can thereafter be assayed for 
astrocyte cell death. However, it is known that astrocytes in vitro substantially differ 
from their in vivo counterparts. To resolve this difference, we also plan to examine 
cell autonomy in vivo by transplanting doubly transgenic Slc25a12 KO; GLT-1-GFP 
astrocytes into wild type, neonatal mouse pups. 
Despite the issue of cell autonomy, we have so far failed to observe Slc25a12 
KO astrocyte cell death in vitro using both mixed primary neuron and astrocyte 
cultures and astrocyte only cultures. Moreover, it is not known whether the astrocytes 
of patients with Slc25a12 loss of function mutations also exhibit cellular apoptosis. 
The creation of an in vitro system that recapitulates in vivo Slc25a12 KO astrocyte 
apoptosis will be essential for identifying metabolic abnormalities that may contribute 
to cell death and for testing small molecules or other therapeutics for their effects on 
preventing cell death. The lack of astrocyte cell death in vitro may be attributed to 
known differences between cultured and in vivo astrocytes, or the high availability of 
glucose and additional glycolytic substrates in the culture media. Future experiments 
include culturing Slc25a12 KO astrocytes in low glucose, low oxygen conditions, 
both of which have been demonstrated to have effects on astrocyte survival (Paquet et 
al., 2013).  
 
Astrocyte apoptosis: Patient profile 
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Astrocytic abnormalities have not been reported in patients with Slc25a12 loss 
of function mutations, and it is not known whether astrocytes from these patients 
undergo apoptosis. We tested this question by generating astrocytes from patient-
derived iPSCs and transplanting them into wild type (NOD-SCID) neonatal mouse 
cortex. Our preliminary experiments suggest that patient astrocytes do not undergo 
apoptosis, even after 3 weeks in vivo. However, it has been well documented that 
human astrocytes have uniquely hominid features that differentiate them from those 
of other mammals (Oberheim et al., 2009). These features include enhanced 
morphological complexity resulting in overlapping patterning, phenotypic diversity of 
GFAP expression, as well the existence of novel astrocyte population, which may 
contribute to or account for the phenotypic discrepancy observed between patient and 
Slc25a12 KO astrocytes. The discrepancy also seems to suggest that astrocyte cell 
death may be a cell non-autonomous effect, since the genotypic in vivo 
microenvironment patient astrocytes were transplanted in was wild type. We plan to 
use Slc25a12 KO mice as transplant recipients in future experiments to further 
explore this question.  
Another possible reason for the survival of patient astrocytes in vivo is the 
difference in Slc25a12 protein functionality between patients and the knockout 
mouse. Unlike the mouse model, which by virtue of being a protein knockout, results 
in 0% protein functionality, the patients (from whom the iPSCs used in this study 
were generated) harbor mutations that confer only a partial loss of function that 
results in 15% protein functionality compared to wild type Slc25a12. It is possible 
that the retention of some, albeit limited, protein functionality is able to sustain 
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astrocyte metabolism enough to promote cell survival. A separate case study 
identified patients with a different mutation in Slc25a12 that conferred 0% protein 
functionality (Wibom et al., 2009). Future studies using derived astrocytes from these 
patients may be able to shed light on this issue.  
Finally, an important caveat to consider is the heterogeneity of astrocytes; a 
multitude of different astrocyte cell types have been identified that differ with respect 
to their morphologies, localization, and transcriptomes (Matyash and Kettenmann, 
2010; Chaboub and Deneen, 2012; Zhang et al., 2014). Using a previously published 
differentiation protocol (Krencik et al., 2011), we were able to differentiate patient-
derived iPSCs into cells that expressed glutamine synthetase and GFAP (not shown). 
However, the current state of not only identification of astrocytic subtypes, but also 
methods for their differentiation from iPSCs is not as advanced as it is for neurons, 
for which there are published subtype specific markers and protocols for 
differentiation into excitatory, motor, and even inhibitory neuron subtypes with fine 
specificity. Though the cells we generated were astrocytic in nature, it is unclear what 
type of astrocyte was generated. Upon transplantation, patient astrocytes did not 
demonstrate localization specificity. Rather, they migrated to every brain region, 
consistent with previous published reports on human astrocyte transplants (Windrem 
et al., 2014). The vast heterogeneity of astrocytes and the current challenge of 
differentiating subtype specific astrocytes from iPSCs must be kept in mind in the 
interpretation of these experiments. 
 
Concluding Remarks 
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 In healthy individuals, mitochondria function optimally to provide energy to 
sustain the metabolic needs of all cell types. In the brain, mitochondria are especially 
important as the brain uses 20% of the body’s basal metabolism. Thus, it is not 
surprising that encephalomyopathy is the most common symptom of mitochondrial 
disease. The diversity of mitochondrial diseases yields heterogeneity in the resulting 
encephalomyopathies. The first step in therapeutic development for seizures resulting 
from mitochondrial disease is identifying and understanding changes in the 
development and function of neural cell types. To this end, the findings described in 
this Chapter provide novel insight on astrocytic contributions to dysregulated 
glutamatergic neurotransmission and seizures in a particular mitochondrial disease 
resulting from Slc25a12 loss of function. In addition, this work underscores the 
importance of studying astrocytes in disease and suggests that cell-targeted 
therapeutics may be a beneficial avenue to explore in treating this disease. 
 
 
 
 
 
 
 
 
 
 
 78 
Experimental Procedures 
Animals 
 Slc25a12 heterozygous mice were re-derived from sperm (a gift from the 
Joseph Buxbaum lab) and out-bred once onto a CD1 genetic background. 
Heterozygous mice were bred with each other to generate homozygous Slc25a12 KO 
mice, which were viable until approximately P22 and born in expected Mendelian 
ratios. For preparation of brain tissue, animals were transcardially perfused with 
phosphate buffer saline (PBS) followed by 4% paraformaldehyde (PFA). Brains were 
removed from the skull, immersed in 4% PFA overnight, washed three times with 
PBS at room temperature. Brains were then mounted in 4% low-melt agarose and 
sectioned at 50 µm using a Leica vibratome. All experiments described in this study 
were performed in accordance with an approved institutional animal care and use 
committee protocol.  
 
Immunohistochemistry 
 Brain sections were blocked for 1 hour at room temperature (5% BSA in 0.1% 
PBS-Triton) and probed in blocking buffer with antibodies recognizing Slc25a12 
(Thermo Scientific, PA5-23778, 1:100), PV (Swant, PV 235, 1:2500), GFP (Abcam, 
ab13970, 1:1000), GABA (Swant, GABA 3A12, 1:500), S100β (Sigma, S2657, 
1:100), cleaved caspase 3 (Cell Signaling, 9664S, 1:400), cleaved PARP (Cell 
Signaling, 9544S, 1:400), CD44 (BD Biosciences, 550538, 1:50), or ADK (gift from 
Boison Detlev, 1:500) overnight at 4°C. The following secondary antibodies were 
used: Alexa-568 goat anti-rabbit (Life Technologies, A-11011, 1:1000), Alexa-488 
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goat anti-mouse (Life Technologies, A-11001, 1:1000), Alexa-488 goat anti-chicken 
(Life Technologies, A-11039, 1:1000), Alexa-568 goat anti-mouse (Life 
Technologies, A-11034, 1:1000).  
 For differentiated patient-derived iPSCs, cells were fixed for 20 minutes at 
room temperature with 4% PFA, washed three times with PBS, blocked blocked for 1 
hour at room temperature (5% BSA in 0.1% PBS-Triton) and probed in blocking 
buffer with an antibody recognizing Nkx2.1 (Abcam, ab72876, 1:100). The secondary 
antibody used was Alexa-568 goat anti-rabbit (Life Technologies, A-11011, 1:1000). 
 
TUNEL assay 
 Floating 50 µm sections were treated with 50 µl of 10 µg/ml Proteinase K in 
10 mM Tris-HCl, pH 7.5 for 5 minutes at 37°C, washed three times in PBS, and then 
incubated in In Situ Cell Death Detection Kit TUNEL reaction mixture (Roche, 
11684795910) according to the manufacturer’s instructions. Positive controls were 
achieved by incubating wild type sections in 3000 U/ml DNase I recombinant (Roche 
4716728001) in 50 mM Tris-HCl, pH 7.5, 1 mg/ml BSA for 10 minutes at room 
temperature.  
 
Imaging and phenotypic analysis  
 Images were acquired using a Photometrics CoolSNAP ES2 camera attached 
to a Nikon Eclipse Ni microscope with NIS Elements AR imaging software. Images 
were processed using Adobe Photoshop and scored using ImageJ Cell Counter tool. 
When counting cells, a cell was considered to be apoptotic or GABAergic if the 
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fluorescent signal was pervasive throughout the cell body or nucleus (representing 
cells on the top plane of the tissue), with nuclear DAPI present. Cells were counted 
only in the hippocampal hilus and did not extend to the region beyond the fork of the 
dentate gyrus. For pixel area quantification in CD44 experiment, thresholding was 
achieved by first calculating the mean and standard deviation (σ) for three randomly 
selected background staining ROIs. Three times the standard deviation above the 
mean was established as the positive detection threshold.  
 
Patient-derived iPSC interneuron differentiation 
 Patient-derived iPSCs were maintained on 5% extracellular matrix (Sigma, 
E6909) in DMEM/F-12 media until confluency. Once confluent, cells were re-plated 
into ECM-coated 24-well plates for differentiation. For differentiation, iPSCs were 
treated with KnockOut Serum Replacement media (Life Technologies, 10828-028) 
supplemented with LDN-193189 (Stemgent, 04-0074, 100 nM), SB431542 
(Stemgent, 04-0010, 10 µM), and XAV939 (Stemgent, 04-00046, 2 µM), hereafter 
referred to as “LSX” media, from differentiation days (Zhang et al.) 0-4. From DD4-
5, iPSCs were treated with 3:1 LSX:N2 media (N2 media consists of DMEM/F-12 
with 0.75 g D-glucose (EM Science, DX0156), 1% glutamax (Gibco, 35050), 1% N2 
supplement B (Stemgent, 07156), 0.1% beta-mercaptoethanol (Life Technologies, 
21985-023), and 0.2% primocin (Life Technologies, Ant-pm-2)). From DD6-7, iPSCs 
were treated with 1:1 LSX:N2 media, and from DD8-9, with 1:3 LSX:N2 media. 
From DD10-18, iPSCs were subject to ventral cell patterning by being treated with 
N2+B27 media containing human Shh (R&D, 1845-SH-0251, 100 ng/mL) and 
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purmorphamine (Stemgent, 04-009, 1 µM). From DD18 onwards, iPSCs were treated 
with Neurobasal media (Gibco, 21103) with B27 supplement (Life Technologies, 
17504).  
 
Video behavioral seizure monitoring 
 P7 to P16 age Slc25a12 KO mice and wild type littermates were placed in 
cage compartment on top of a heated pad for 1 hour. Behavioral seizures were 
recorded with a digital video camera (Stellate Systems; Harmonie, version 5.0b).  
 
Western assay 
 To generate hippocampal protein lysates, brains were quickly dissected on dry 
ice and hippocampus was isolated from the overlying cortex. Tissues were placed in 
pre-weighed Eppendorf tubes, and 1 ml RIPA lysis buffer with protease inhibitor 
(Sigma, P8340, 1:100) was added per 200 mg tissue. Tissues were homogenized 
using a handheld tissue homogenizer, agitated for 2 hours at 4°C, then centrifuged at 
12,000 RPM for 20 minutes. 5, 10, and 40 µg protein for the detection of GLT-1, 
GLAST, and ADK respectively, were loaded into 4-12% Bis-Tris Plus Gels (Life 
Technologies, BG04120BOX), electrophoresed for 40-60 minutes at 80V, then 
transferred onto nitrocellulose membranes using the iBlot dry blotting system (Life 
Technologies, IB1001). Membranes were incubated for 1 hour at room temperature in 
Odyssey blocking buffer (Licor, 927-50000), washed three times in PBS with 0.1% 
Tween (PBS-T), then incubated overnight at 4° in with antibodies recognizing GLT-1 
(Jeffrey Rothstein lab, 1:5000), GLAST (Miltenyi Biotec, 130-095-822, 1:50), and 
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ADK (Detlev Boisson lab, 1:6000). After washing membranes three times with PBS-
T, membranes were incubated with Licor Odyssey secondary antibodies according to 
the manufacturer’s instructions, and developed and quantified using the Odyssey CLx 
Infrared Imaging System (Licor) and Image Studio Lite software (Licor). 
 
Electrophysiology  
 Mice aged P13-P17 were anesthetized with isoflurane and decapitated. Brains 
were dissected out placed immediately in bubbled ice cutting solution (2.5 mM KCl, 
1.25 mM NaH2PO4, 218 mM sucrose, 26 mM NaHCO3, 10 mM D-glucose, 0.5 mM 
CaCl2, 10 mM MgSO4, with 95% O2 and 5% CO2 and 285 mOsM). Brains were 
bisected down the midline and mounted on a cutting stage angled at 12-15 degrees to 
produce 350 µm thick hippocampal entorhinal cortex sagittal slices. Slices were 
placed in bubbled artificial cerebrospinal fluid (130 mM NaCl, 2.75 mM KCl, 1.1 
mM NaH2PO4, 28.82 mM NaHCO3, 11.1 mM D-glucose, 2.5 mM CaCl2, 1.43 mM 
MgSO4 with 315 mOsM) for 30 minutes at 37°C, then at room temperature for 1 hour 
prior to recording. For mEPSC and sIPSP recordings, pyramidal cells in CA3 were 
patched with an internal pipette solution consisting of 5 mM KCl, 135 mM K-
gluconate, 2 mM NaCl, 10 mM HEPES, 4 mM EGTA, 4 mM MgATP, 0.3 mM 
Na3GTP, with a pH of 7.2 and osmolarity of 285 mOsM. Cells were held at -60 mV 
in the presence of 0.5 µM tetrodotoxin (mEPSC) and -40 mV (sIPSP). After 
recording, cells were filled with neurobiotin (Vector Labs, SP-1120) for post-
recording processing.  
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ADK inhibitor treatment 
ABT-702 (Tocris, 2372) was reconstituted in sterile DMSO. Mice will be 
given daily intraperitoneal injections of 10 mg/kg ABT-702 in sterile PBS (Tocris, 
2372) from P10-P16, 12 hours before prior to the assessment of behavioral seizures 
by video monitoring.  
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Figure 3.1. Slc25a12 (AGC) is localized to the inner mitochondrial membrane 
where it is a part of the malate aspartate shuttle.  
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Figure 3.1. Slc25a12 (AGC) is localized to the inner mitochondrial membrane 
where it is a part of the malate aspartate shuttle. 
 
As part of the malate-aspartate shuttle with the oxoglutarate carrier (OGC), Slc25a12 
(shown here as AGC) catalyzes the exchange of intramitochondrial aspartate and 
cytosolic glutamate plus a proton. This process brings NADH from the cytosol to the 
mitochondria, where its electrons participate in the electron transport chain to 
generate ATP for the cell.  
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Figure 3.2. Slc25a12 is expressed in neurons, interneurons, and astrocytes 
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Figure 3.2. Slc25a12 is expressed in neurons, interneurons, and astrocytes 
 
A) Fluorescence immunohistochemistry for Slc25a12 (red) in P16 wild type (left) 
and Slc25a12 KO (right) mouse cortex. Dorsal is up.  
B) Fluorescence immunohistochemistry for Slc25a12 (red) and parvalbumin (green) 
in P16 wild type mouse brain. Open arrowhead indicates cells that co-express 
Slc25a12 and parvalbumin. Closed arrowheads show cells that express only 
Slc25a12.  
C) Fluorescence immunohistochemistry for Slc25a12 (red) and GFP (green, driven 
by GLT-1/BAC). Open arrowhead indicates cells that co-express Slc25a12 and 
GFP. Closed arrowheads show cells that express only Slc25a12.  
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Figure 3.3. Loss of Slc25a12 does not adversely impact interneuron development 
and differentiation 
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Figure 3.3. Loss of Slc25a12 does not adversely impact interneuron development 
and differentiation 
 
A) Fluorescence immunohistochemistry for GABA (red) and DAPI (blue) of P11 
wild type and Slc25a12 KO hippocampus (left). Quantification of GABA cell 
counts (right). Data were analyzed by two-tailed Student’s t-test. Error bars 
indicate SEM.  
B) Patient-derived induced pluripotent stem cell protocol for differentiation into 
putative interneurons.  
C) Fluorescence immunocytochemistry for the putative interneuron marker Nkx2.1 
(red) and DAPI (blue) on Slc25a12 loss of function patient-derived induced 
pluripotent stem cells differentiated into ventralized, putative interneurons after 
40 days of differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 90 
Figure 3.4. Slc25a12 KO results in hippocampal selective astrocyte apoptosis. 
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Figure 3.4. Slc25a12 KO results in hippocampal selective astrocyte apoptosis. 
A) Fluorescence immunohistochemistry for the apoptotic marker cleaved caspase 3 
(red) and S100β (green) in P16 wild type (top panel) and Slc25a12 KO (bottom 
panel) hippocampus. DG indicates dentate gyrus. 
B)  Quantification of the astrocytes expressing apoptotic markers cleaved caspase 3 
or cleaved PARP. Data were analyzed by two-tailed Student’s t-test. * indicates 
p<0.05 compared to wild type. Error bars indicate SEM.  
C) Fluorescence immunohistochemistry for the apoptotic marker cleaved PARP 
(red), on left, and fluorescein-conjugated TUNEL reaction (green), on right.  
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Figure 3.5. Astrocyte apoptosis is accompanied by compensatory increase in 
astrocyte numbers and precedes the onset of behavioral seizures. 
 
 
 
 
 
 
 
 
 
 
 
 
 93 
Figure 3.5. Astrocyte apoptosis is accompanied by compensatory increase in 
astrocyte numbers and precedes the onset of behavioral seizures. 
 
A) Inverted image of fluorescence immunohistochemistry for CD44 (dark) in P11 
wild type and Slc25a12 KO hippocampus (left). Quantification of pixel area 
(right). Thresholding for CD44 signal was achieved by first calculating the mean 
and standard deviation (σ) for three randomly selected background staining ROIs. 
Three times the standard deviation above the mean became the positive detection 
threshold. DG indicates dentate gyrus. Data were analyzed using two-tailed 
Student’s t-test. * indicates p<0.05. Error bars indicate SEM.  
B) Quantification of hippocampal astrocyte number at P11 (blue) and P16 (red). 
Solid bars indicate wild type, and hatched bars indicate Slc25a12 KO. Data wre 
analyzed using two-tailed Student’s t-test. * indicates p<0.05. Error bars indicate 
SEM.  
C) Line chart illustrating time of onset for astrocyte apoptosis and behavioral 
seizures in wild type and Slc25a12 KO mice. 
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Figure 3.6. Hippocampal astrocyte apoptosis is not apparent in mice deficient in 
the transcription factor Arx.  
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Figure 3.6. Hippocampal astrocyte apoptosis is not apparent in mice deficient in 
the transcription factor Arx.  
 
Fluorescence immunohistochemistry for the apoptotic marker cleaved caspase 3 (red) 
and S100β (green) in P16 Arx(GCG)10+7 mice (n=2). 
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Figure 3.7. Slc25a12 KO astrocytes down-regulate expression of glutamate 
transporters GLT-1 and GLAST.  
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Figure 3.7. Slc25a12 KO astrocytes down-regulate expression of glutamate 
transporters GLT-1 and GLAST.  
 
Representative blots for GLT-1 and GLAST are shown on the left panel. 
Quantification of blot intensity on right. Data were analyzed with two-tailed Student’s 
t-test.  * indicates p<0.05. Error bars indicate SEM.  
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Figure 3.8. Electrophysiology of Slc25a12 KO pyramidal cells indicate evidence 
of synaptic glutamate retention.  
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Figure 3.8. Electrophysiology of Slc25a12 KO pyramidal cells indicate evidence 
of synaptic glutamate retention.  
 
A) Histogram depicting the number of events for a bin of amplitudes for wild type 
(green) and Slc25a12 KO (blue) on left, followed by cumulative probability K-S 
curve for amplitude, on right.  
B) Inter-event interval cumulative probability K-S curve for wild type (green) and 
Slc25a12 KO (green). 
C)  Histogram depicting the number of events for a bin of mEPSP areas for wild type 
(green) and Slc25a12 KO (blue) on left, followed by cumulative probability K-S 
curve for mEPSP area, on right.  
D) mEPSP decay cumulative probability K-S curve for wild type (green) and 
Slc25a12 KO (green). 
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Figure 3.9. Slc25a12 KO astrocytes up-regulate expression of the 
neuromodulatory kinase ADK.  
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Figure 3.9. Slc25a12 KO astrocytes up-regulate expression of the 
neuromodulatory kinase ADK. 
 
A) Fluorescence immunohistochemistry for ADK (red) in hippocampus of P16 wild 
type and Slc25a12 KO mice. SR, SLM, SM, DG indicate stratum radiatum, 
stratum lacunosum moleculare, stratum moleculare, and dentate gyrus 
respectively.  
B) Representative blots for ADK are shown on the top panel. Band intensity was 
quantified for both long and short isoforms, and was not significantly different 
between wild type and KO. The quantification of total band intensity is shown on 
the bottom panel. Data were analyzed with two-tailed Student’s t-test. Error bars 
indicate SEM.  
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Chapter 4 
Future Directions 
 
 The first part of my thesis research found an unprecedented association 
between the human papillomavirus type 16 oncoprotein E6 and human focal cortical 
dysplasia type IIB (FCDIIB) through the detection of E6 DNA, mRNA, and protein 
in FCDIIB brain specimens that is not detected in controls. Additionally, my research 
established a functional link between E6 expression and the development of cortical 
malformations in an acute mouse model of focal cortical malformations. Several 
questions on how HPV can infect the brain remain unanswered, including the mode 
of HPV transmission to the brain and the putative unique tropism of HPV for 
epithelial cells. In addition, my thesis work raised several broader questions, 
including whether these findings are reproducible and what they mean for the general 
population and the incidence of epilepsy and HPV. 
 The second part of my research uncovered a novel, hippocampal astrocyte 
apoptosis phenotype accompanied by increased astrocyte turnover, down-regulation 
of the glutamate reuptake transporter GLT-1, and up-regulation of adenosine kinase, 
resulting from Slc25a12 knockout. Because of the role astrocytes play in modulating 
excitatory glutamatergic neurotransmission, these findings suggest that excitotoxic 
glutamatergic neurotransmission preceded by astrocyte abnormalities is the root of 
seizures in the Slc25a12 KO mouse model. This work raises interesting questions 
about developmental and compensatory astrocyte homeostasis, such as whether 
astrocyte maturation is delayed and whether the astrocytic expression of apoptotic 
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markers is a definitive indicator of cellular apoptosis. In this chapter, I will discuss 
experimental approaches to answer these questions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
Part 1 
HPV mode of transmission 
Because it is believed that FCDIIB forms during embryonic brain 
development, the question of how HPV infection is acquired or transmitted remains. 
One highly appealing possibility is transplacental HPV16 infection of neuroglial 
progenitor cells in utero during brain development. The transplacental HPV 
transmission rate has been reported as 12.2% (Rombaldi et al., 2008), and as the 
prevalence of HPV infection is estimated at 26.8% (Dunne et al., 2007) in the United 
States, transplacental transmission of HPV16 is a plausible mechanism for entry into 
the brain (Figure 4.1). Alternatively, it is conceivable that the effects of HPV16 E6 
could lead to FCDIIB formation in the early neonatal period.  
Unfortunately, there is no easy experimental model to validate transplacental 
transmission. In vitro models, such as the mouse vaginal challenge model, are 
insufficient since real human papillomaviruses are dangerous to work with and not 
readily isolatable. One possibility is to conduct a retrospective correlational study on 
the HPV status of the parents of FCDIIB patients. However, this would be speculative 
at best, since there is no effective means of knowing whether a parent was infected 
with HPV before or after the birth of an FCDIIB patient. Since the advent of the HPV 
vaccine, prospective studies on the incidence of FCDIIB are now possible.  
 
The tropism of human papillomavirus: Can HPV infect the brain? 
 Human papillomavirus type 16 is widely known as the virus that causes 
cervical cancer, and it is generally believed that HPV displays unique tropism for 
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epithelial cells. However, recent research has yielded an increasing body of evidence 
indicating that this may not be this case. HPV has been detected in peripheral nerves 
adjacent to oropharyngeal cancers and in spermatozoa (Füle et al., 2006; Foresta et 
al., 2011). Additionally, the detection of HPV genomic elements and oncoproteins in 
human FCDIIB brain provides further evidence for the widespread tropism of HPV. 
HPV infection has been demonstrated in vitro and in vivo to occur through the 
binding of viral capsid protein L1 to cell surface HSPGs (Giroglou et al., 2001; 
Horvath et al., 2010; Schiller et al., 2010). Additional studies have specified 
syndecan-1 as the critical HSPG needed for HPV binding and infection (Shafti-
Keramat et al., 2003; Knappe et al., 2007). Syndecan-1, a type I transmembrane 
HSPG and a member of the syndecan proteoglycan family is highly expressed in 
neuroglial progenitor cells in the ventricular zone of the developing brain, but not in 
mature neurons (Nakanishi et al., 1997), suggesting that neuroglial progenitor cells 
may be susceptible to infection by HPV during development.  
One experiment that can answer the question of whether neuroglial progenitor 
cells can be infected by HPV is to culture murine neuroglial progenitor cells 
(mNPCs) with HPV pseudoviruses. Pseudoviruses are commonly used in HPV 
research as they do not contain viral genomes and are considered biologically safe 
reagents. They are generated by introducing two plasmids into 293TT cells: one 
encoding both viral capsid proteins L1 and L2; and the other, which serves as the 
viral “pseudogenome,” encoding E6-GFP under the control of the SV40 origin of 
replication. Viral capsid proteins assemble in vitro and encapsulate the 
pseudogenome. The resultant pseudoviruses can then be extracted by detergent lysis 
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and purified using density gradient ultracentrifugation. 
mNPC infectability can be assayed by co-culturing with HPV pseudoviruses. 
Infection is achieved when the pseudogenome containing GFP is transmitted to the 
host cell. The necessity of syndecan-1 for HPV pseudovirus infection can be tested by 
stably knocking down syndecan-1 in mNPCs and assaying for infection. The ability 
of syndecan-1 to facilitate HPV pseudovirus infection on its own can also be tested by 
transiently transfecting syndecan-1 into K562 cells (which do not normally express 
syndecan-1).  
It is possible that L1 may bind syndecan-1, but mNPCs may not be infected. 
As pseudoviruses have been demonstrated to be agents of infection in other cell types 
that express syndecan-1, this suggests that perhaps other proteins may be involved in 
facilitating pseudovirus infection that may not be expressed in mNPCs, but may be 
expressed in cells of an earlier developmental time point, such as neural stem cells. 
Additionally, L1 may not bind syndecan-1, but mNPCs may become infected. 
However, given that the dissociation constant of L1 to heparan sulfate groups is in the 
range of 10-5-10-7 M in vitro (Sun et al., 2010), the possibility that L1 will not bind 
syndecan-1 is very low. However, if there is no binding, it would suggest that HPV 
pseudoviruses use other proteins to facilitate infection in mNPCs and that the 
mechanism of HPV infection in neural cell types is unique and different from that 
which governs epithelial cells.  
Lastly, L1 may not bind syndecan-1 in any neural cell type suggesting that 
there may be species-specific interactions inhibiting HPV pseudovirus binding and 
infection or neural cell types are unable to be infected by HPV. In the case of the 
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former, a reasonable follow-up experiment would be to test HPV pseudovirus 
infectability in human neuroglial progenitor cells, which are commercially available. 
In the case of the latter, it is possible that HPV can enter the brain by virtue of 
somatic genome integration when an infected sperm fertilizes an oocyte.  
 
Reproducibility of results 
 Since the publication of the data in Chapter 2, three independent groups have 
repeated this study to varying results. The first of these published reports, published 
in 2014 (Liu et al., 2014), conducted PCR and immunohistochemistry for HPV on 27 
FCDIIA and 20 FCDIIB specimens. Their data indicate that HPV16 was detected in 
90% of FCDIIB and 22.2% of FCDIIA specimens. My thesis research indicated that 
HPV16 E6 was present in balloon cells of FCDIIB, making its detection in FCDIIA, a 
focal malformation disorder without balloon cells, an interesting finding. In addition 
to detecting HPV, Liu and colleagues also detected four other common intrauterine 
infection-related viruses – cytomegalovirus (19.1%), human herpes virus-6B (12.7%), 
and herpes simplex virus-1 (31.9%) in non-specified FCD specimens. Of 36 normal 
brain specimens examined, only 2 were positive for viral expression (not specified). 
While their data support the findings of Chapter 2, the discovery of additional viruses 
in FCD specimens detracts from the hypothesized causal association between HPV 
and FCDIIB, as it is not known how the other viruses affect mTOR signaling and 
brain development. Cytomegalovirus in particular, and herpes simplex virus-1 to a 
lesser extent, have both been associated with seizures in a number of reports (Jay et 
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al., 1995; Suzuki et al., 2008), suggesting that viral infection and propagation may be 
a common denominator in the alteration of early brain development.  
The other two reports, both published in 2015, were unable to replicate our 
findings. In the first (Shapiro et al., 2015), 14 distinct FCDIIB specimens obtained 
from one surgical center were tested for HPV using PCR, in situ hybridization, 
chromogenic in situ hybridization, and immunohistochemistry. HPV was not detected 
by PCR, in situ hybridization, or chromogenic in situ hybridization. They expressed 
concern about degraded DNA quality from tissue specimens, citing that 7 of the 14 
specimens failed to generate an adequate amplicon, leaving the amplicons detected in 
the other 7 samples subject to investigation. No mention was made as to the size of 
the amplicons detected, or whether sequencing analysis was conducted. Shapiro and 
colleagues conducted immunohistochemistry for p16INK4a, a cyclin-dependent 
kinase inhibitor that is highly associated with HPV infection and used as a surrogate 
marker of HPV infection, and found that 3 of 10 cases examined exhibited 
immunoreactivity in balloon cells. HPV16 E6 immunohistochemistry was not 
conducted. The discrepancy between the findings of Shapiro and colleagues and the 
findings presented in Chapter 2 may be due to the variability in the rate of HPV 
infection in various populations. The cohort used in this study came from a single 
surgical center, which may be located in an area with low HPV exposure. The authors 
are quick to point out that the animal model in our study did not contain dysmorphic 
neurons and balloon cells. It is possible that the temporal expression of E6 (5 days) 
was too short to result in morphological cellular deficits. Future studies will need to 
 117 
be conducted on postnatal mice to determine whether extended expression of E6 will 
result in cytopathic effects concomitant with eventual seizures.  
 The third and last published report on FCDIIB and HPV probed 14 FCDIIB 
specimens using 4 PCR primers for HPV DNA and antibodies against E6 (Coras et 
al., 2015). Interestingly, all 14 specimens did not yield amplicons for HPV DNA, and 
immunohistochemistry for E6 revealed weak staining in FCDIIB specimens as well 
as in TSC specimens, attributed to a non-specific antibody and technical pitfalls when 
using formalin-fixed paraffin-embedded brain tissues. No antibody controls were 
conducted.  
The lack of HPV detection by PCR by two of three research groups is puzzling. It is 
possible that HPV DNA can exist as an episome or as an integrated genome in the 
host cell nucleus. Perhaps HPV DNA that has successfully integrated is more 
amenable to amplification by PCR. In the case of the former, detection would be 
more likely using in situ hybridization, which Shapiro and colleagues conducted, with 
no detection. Considering these differing findings, it is clear that the association 
between HPV16 and FCDIIB is highly contested and will not be resolved without 
more replication and research.  
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Part 2 
Region-specific astrocyte apoptosis/mechanism of astrocyte apoptosis 
In human temporal lobe epilepsy as well as many seizure models, neuronal 
cell death is evident in the hippocampus. For astrocytes, however, the literature on 
apoptosis is very sparse. Since the time of Santiago Ramon y Cajal, astrocytes have 
garnered a reputation for being hardier than neurons. Thus, our finding that astrocytes 
undergo apoptosis in the hippocampus before the onset of behavioral seizures is both 
novel and unprecedented. However, the mechanism underlying how loss of Slc25a12 
leads to astrocyte cell death is still unknown.  
Though we have made every effort to be rigorous in the analysis of the 
timeline of the onset of both astrocyte apoptosis and behavioral seizures, one 
possibility that we must consider is that seizure-like electroencephalographic (EEG) 
abnormalities can be present without, and possibly before, the onset of behavioral 
manifestations. However, measuring EEG in mouse pups under 2 weeks of age 
remains a challenge due to the non-availability of small electrode devices and set ups 
that accommodate the small size of pups. This limitation is reflected in the current 
studies on Slc25a12 KO mice, which have not examined EEGs earlier than P15 
(Gómez-Galán et al., 2012). However, even current studies raise more questions than 
answers. Analyzing local field potentials (LFP) from hippocampus of wild type and 
Slc25a12 KO mice aged P16 to P22, one group reported reduced LFP power in 
Slc25a12 KO (Gómez-Galán et al., 2012), which is inconsistent with LFPs recorded 
from other seizure models (Queiroz et al., 2009; Keller et al., 2010). They argued that 
their LFPs are generated from hippocampal inhibitory interneurons by citing a deficit 
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in gamma oscillations (waveforms propagated by GABAergic interneurons) as well 
as a reduction in glutamic acid decarboxylase in Slc25a12 KO animals. Their 
evidence suggests that Slc25a12 KO mice are deficient in GABA, implicating 
GABAergic interneurons as the major driver of seizure genesis in Slc25a12 KO 
animals. We submit that there may be global network deficiencies in Slc25a12 KO 
mice, including contributions from GABAergic interneurons. However, our analyses 
have pointed us toward the astrocyte as the major contributor in seizure genesis, as 
GABAergic interneurons are largely unaffected by Slc25a12 KO. 
 To account for astrocytic cell death, one possibility to consider is the role of 
astrocytic metabotropic glutamate receptor 5 (mGluR5). Astrocytic mGluR5 has a 
demonstrated role in neuron-glia interactions, including the regulation of glutamate 
reuptake (Vermeiren et al., 2006), and the expression of mGluR5 has also been shown 
to be up-regulated in some models of epilepsy (Ferraguti et al., 2001; Aronica et al., 
2003). Additionally, in one study of murine primary cortical astrocyte cultures, 
enhanced astrocytic mGluR5 expression resulting from oxygen glucose deprivation 
resulted in the activation of phospholipase C and release of intracellular calcium 
stores, leading to subsequent astrocyte cell death (Paquet et al., 2013). Though this 
mechanism of astrocyte cell death has not been demonstrated in vivo, it is possible 
that Slc25a12 KO cells experience partial glucose and oxygen deprivation by virtue 
of their inability to maximally utilize glucose and oxygen (Pardo et al., 2011). This 
partial deprivation may also explain the localized specificity of astrocyte cell death, 
as brain regions vary in their metabolic demands, lending those regions with higher 
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demands, such as the hippocampus, to be increasingly susceptible to perturbations in 
glucose utilization. 
 One possibility that is appealing to speculate upon is that the expression of 
cleaved caspase 3 and cleaved PARP in Slc25a12 KO astrocytes are not actually 
indicators of cellular apoptosis, but rather, are expressed proteins that are used for 
other cellular processes. Indeed, in addition to the role of apoptotic executioner 
proteins in morphogenesis, cellular maturation, and differentiation, apoptotic 
executioner proteins have also been demonstrated to be critical in compensatory 
cellular proliferation and regeneration in many species, including mouse (Carlile et 
al., 2004; Sztiller-Sikorska et al., 2009; Khalil et al., 2012; Miura, 2012). It is worth 
noting that it is the uncleaved isoforms of these executioner caspases that are 
involved in these various cellular processes. Therefore, given that the astrocytes in 
Slc25a12 KO hippocampus exhibit robust cleaved caspase 3 and cleaved PARP, 
proteins in the final common pathway of apoptosis, it is very likely the astrocytes in 
Slc25a12 KO are undergoing apoptosis, and not facilitating the regulation of another 
cellular process.  
 
Astrocyte maturation 
 The increased expression of the immature astrocyte marker CD44 begs the 
question of whether astrocytes are truly undergoing compensatory cell turnover or 
whether astrocytes simply fail to mature properly. In support of the failure to achieve 
maturation hypothesis, immature astrocytes consistently express reduced levels of 
glutamate reuptake transporter GLT-1 in comparison to mature astrocytes (Furuta et 
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al., 1997; Kugler and Schleyer, 2004). The fact that we see down-regulated levels of 
GLT-1 in Slc25a12 KO hippocampus supports this hypothesis. However, it is worth 
noting that we have also observed GLT-1 reduction in cortical protein lysates of 
Slc25a12 KO brains (data not shown). The expression of CD44 in Slc25a12 KO 
mouse brain, however, is restricted to the hippocampus. The presence of astrocyte 
precursor cells in the region of the hippocampus where astrocyte apoptosis is 
occurring is not coincident, and suggests that astrocytes undergo cell turnover in the 
hippocampus to account for dying cells. Since it had been previously demonstrated 
that astrocytes undergo local proliferation (Ge et al., 2012), this hypothesis is likely to 
be a possibility.  
 
Nuclear sequestration of ADK in Slc25a12 KO astrocytes 
Our finding of enhanced localization of ADK-L in astrocytic nuclei is not 
consistent with previous findings in mouse seizure models of increased ADK-S 
localization in astrocytic cytoplasm. Furthermore, the discrepancy between the 
immunohistochemical and Western data is puzzling. It is possible that putative 
increases in nuclear ADK levels may be masked by the total amount of protein 
present. The differential functions of the two ADK isoforms have not been elucidated 
to date. So far, there is evidence to suggest that cytoplasmic ADK (ADK-S) may be 
responsible for maintaining the balance of extracellular adenine nucleotides, while 
nuclear ADK (ADK-L) contributes to epigenetic functions related to cell proliferation 
(Cui et al., 2009). It is unclear whether nuclear localization of ADK shares the same 
linkage to seizures as the previously established cytoplasmic ADK. Western assays 
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on proteins from nuclear and cytoplasmic fractionation may help us resolve the true 
extent of ADK expression and localization. However, it is appealing to speculate that 
enhanced nuclear ADK-L in astrocytes may play a role in the enhancement of 
astrocyte numbers we observed at P16, due to its putative effects on cell proliferation. 
More studies, such as an astrocyte-specific ADK knockdown need to be conducted in 
order to establish a mechanism of action linking nuclear ADK and astrocyte 
proliferation.  
 
ADK inhibition and treating seizures  
 Our data suggesting a link between astrocytes, ADK, and glutamate on 
seizures prompted us to investigate whether reinstating adenosine-modulated 
inhibitory tone would ameliorate behavioral seizures. To this extent, we plan to treat 
Slc25a12 KO mice with the ADK inhibitor 4-amino-5-(3-bromophenyl)-7-(6-
morpholino-pyridin-3-yl)pyrido[2,3-d]pyrimidine, (ABT-702) and monitor them for 
behavioral seizures, as described previously. ADK inhibitors have been used to 
effectively treat and prevent seizures in animal models (Li et al., 2008). ABT-702 is 
9-fold more potent than other ADK inhibitors such as 5-iodotubercidin (5-IT), and 
works by binding to the phosphorylation site on adenosine where ADK would 
normally bind, preventing it from interacting with ADK (Jarvis et al., 2000). It is 
highly selective for this region, as it has not been demonstrated to bind to other sites 
of adenosine interaction, such as with the A1, A2A, A3 receptors and the adenosine 
transporter and deaminase binding regions, and its binding affinity for this site is high 
(Ki = 1.4 ± 0.8 nM) (Jarvis et al., 2000). Though structure-activity relationships and 
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computational modeling indicate that the half-life of ABT-702 is short at 2.42 hours, 
it is longer than that of 5-IT and its high binding affinity suggests that though free 
ABT-702 may be degraded in a short amount of time, the effects of bound ABT-702 
are long lasting (Zheng et al., 2001).   
 Inhibiting the activity of ADK can result in sedation due to its effects on 
increasing bioavailable adenosine. In a pilot study, we determined that 10 µg/kg (i.p.) 
daily for young mouse pups resulted in minimal sedation that resolved itself within 12 
hours. We will be administering this dose to mouse pups from P10-P16 and 
monitoring for behavioral seizures using video recording. As previously speculated, 
the link between ADK and seizures in Slc25a12 KO is tenuous considering its nuclear 
localization. Furthermore, the ability of ABT-702 to cross the nuclear membrane is 
unknown. If ABT-702 treatment results in minimal seizure amelioration, other 
avenues such as activators of glutamate reuptake transporters or apoptotic inhibitors 
can be explored. Evidence in the human and animal models of epilepsy literature cites 
the efficacy of the ketogenic diet for ameliorating seizures related to metabolic 
deficiencies (Beniczky et al., 2010; Noh et al., 2003; Yudkoff et al., 2005). In 
Slc25a12 KO mice however, we have found that the ketogenic diet given to Slc25a12 
KO pups through consumption by the dam, caused both pups and dams to lose weight 
and may have contributed to premature pup death. There is evidence to suggest that 
implementing the ketogenic diet during gestation alters brain structure and embryonic 
organ growth leading to postnatal dysfunction (Sussman et al., 2013a; Sussman et al., 
2013b). Because the brain is still developing in neonatal mice, it is possible that 
neonatal administration of ketogenic diet may contribute to altered brain structure and 
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metabolic status as seen in pups treated in utero. In light of the astrocyte pathology 
observed in Slc25a12 KO mice, we submit that a more astrocyte-centric approach to 
therapy, such as ADK inhibitors, may be beneficial in treating seizures.  
 
Other effects of Slc25a12 loss of function 
 Though most studies in the literature have focused on the role of Slc25a12 on 
generating ATP, loss of Slc25a12 affects other cellular processes as well. As 
mentioned previously, the role of Slc25a12 in cells is to shuttle reducing equivalents 
(NADH), which are otherwise unable to cross the inner mitochondrial membrane, 
into the mitochondria. When the ratio of NADH to NAD+ becomes high in the 
cytosol, as it would if Slc25a12 was not functioning properly, glycolysis, which uses 
NAD+ as an intermediate, will shut down. This results in a metabolic “double-hit,” 
where the cell with deficient Slc25a12 is not only deficient in oxidative 
phosphorylation, but also in the secondary mechanism of energy production, 
glycolysis. This may result in a build up of lactate, which can be toxic to cells. 
However, in our preliminary analysis, we (and others) did not observe an increase in 
lactate production in vivo by magnetic resonance spectroscopy (Pardo et al., 2011) or 
in vitro using conditioned media from mixed and astrocyte only cultures (data not 
shown), indicating that there may be compensatory shuttling of reducing equivalents 
by other transporters such as the glycerol-3-phosphate shuttle.  
 Another often over-looked function of Slc25a12 is its calcium-binding N-
terminal. Slc25a12 requires the binding of calcium to facilitate its transporter 
capabilities; in situations where Slc25a12 protein function or expression is reduced, it 
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is possible that the cell may experience a build-up of intra-mitochondrial calcium, 
which can affect many processes, including cellular excitability. Imaging 
mitochondria using calcium dyes would enable us to determine whether an increase in 
intra-mitochondrial calcium is occurring, and additional experiments to determine the 
morphology and localization of mitochondria would shed light on whether Slc25a12 
loss of function results in additional mitochondrial dysfunction.  
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Figure 4.1. Hypothesized model of HPV infection in utero.  
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Figure 4.1. Hypothesized model of HPV infection in utero. 
A single cell is infected transplacentally, where it proliferates and passes the viral 
load on to its daughter cells. The infected cells activate the mTOR signaling cascade 
and become cytomegalic,, leading to a focal malformation, surrounded by healthy 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128 
References  
Aronica E, Gorter JA, Jansen GH, van Veelen CW, van Rijen PC, Ramkema M, 
Troost D (2003) Expression and cell distribution of group I and group II metabotropic 
glutamate receptor subtypes in taylor-type focal cortical dysplasia. Epilepsia 44:785-
795. 
 
Beniczky S, Jose Miranda M, Alving J, Heber Povlsen J, Wolf P (2010) Effectiveness 
of the ketogenic diet in a broad range of seizure types and EEG features for severe 
childhood epilepsies. Acta neurologica Scandinavica 121:58-62. 
 
Carlile GW, Smith DH, Wiedmann M (2004) Caspase-3 has a nonapoptotic function 
in erythroid maturation. Blood 103:4310-4316. 
 
Coras R, Korn K, Bien CG, Kalbhenn T, Rossler K, Kobow K, Giedl J, Fleckenstein 
B, Blumcke I (2015) No evidence for human papillomavirus infection in focal 
cortical dysplasia IIb. Annals of neurology 77:312-319. 
 
Cui XA, Singh B, Park J, Gupta RS (2009) Subcellular localization of adenosine 
kinase in mammalian cells: The long isoform of AdK is localized in the nucleus. 
Biochemical and biophysical research communications 388:46-50. 
 
Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz 
LE (2007) Prevalence of HPV infection among females in the United States. Jama 
297:813-819. 
 
Ferraguti F, Corti C, Valerio E, Mion S, Xuereb J (2001) Activated astrocytes in areas 
of kainate-induced neuronal injury upregulate the expression of the metabotropic 
glutamate receptors 2/3 and 5. Experimental brain research 137:1-11. 
 
Foresta C, Patassini C, Bertoldo A, Menegazzo M, Francavilla F, Barzon L, Ferlin A 
(2011) Mechanism of human papillomavirus binding to human spermatozoa and 
fertilizing ability of infected spermatozoa. PloS one 6:e15036. 
 
Fule T, Mathe M, Suba Z, Csapo Z, Szarvas T, Tatrai P, Paku S, Kovalszky I (2006) 
The presence of human papillomavirus 16 in neural structures and vascular 
endothelial cells. Virology 348:289-296. 
 
Furuta A, Rothstein JD, Martin LJ (1997) Glutamate transporter protein subtypes are 
expressed differentially during rat CNS development. The Journal of neuroscience : 
the official journal of the Society for Neuroscience 17:8363-8375. 
 
Ge WP, Miyawaki A, Gage FH, Jan YN, Jan LY (2012) Local generation of glia is a 
major astrocyte source in postnatal cortex. Nature 484:376-380. 
 
 129 
Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M (2001) Human papillomavirus 
infection requires cell surface heparan sulfate. Journal of virology 75:1565-1570. 
 
Gomez-Galan M, Makarova J, Llorente-Folch I, Saheki T, Pardo B, Satrustegui J, 
Herreras O (2012) Altered postnatal development of cortico-hippocampal neuronal 
electric activity in mice deficient for the mitochondrial aspartate-glutamate 
transporter. Journal of cerebral blood flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow and Metabolism 32:306-317. 
 
Jarvis MF, Yu H, Kohlhaas K, Alexander K, Lee CH, Jiang M, Bhagwat SS, 
Williams M, Kowaluk EA (2000) ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-
morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine 
kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro 
characterization and acute antinociceptive effects in the mouse. The Journal of 
pharmacology and experimental therapeutics 295:1156-1164. 
 
Jay V, Becker LE, Otsubo H, Cortez M, Hwang P, Hoffman HJ, Zielenska M (1995) 
Chronic encephalitis and epilepsy (Rasmussen's encephalitis): detection of 
cytomegalovirus and herpes simplex virus 1 by the polymerase chain reaction and in 
situ hybridization. Neurology 45:108-117. 
 
Keller CJ, Truccolo W, Gale JT, Eskandar E, Thesen T, Carlson C, Devinsky O, 
Kuzniecky R, Doyle WK, Madsen JR, Schomer DL, Mehta AD, Brown EN, 
Hochberg LR, Ulbert I, Halgren E, Cash SS (2010) Heterogeneous neuronal firing 
patterns during interictal epileptiform discharges in the human cortex. Brain : a 
journal of neurology 133:1668-1681. 
 
Khalil H, Peltzer N, Walicki J, Yang JY, Dubuis G, Gardiol N, Held W, Bigliardi P, 
Marsland B, Liaudet L, Widmann C (2012) Caspase-3 protects stressed organs 
against cell death. Molecular and cellular biology 32:4523-4533. 
 
Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, Lindahl U, 
Sapp M (2007) Surface-exposed amino acid residues of HPV16 L1 protein mediating 
interaction with cell surface heparan sulfate. The Journal of biological chemistry 
282:27913-27922. 
 
Kugler P, Schleyer V (2004) Developmental expression of glutamate transporters and 
glutamate dehydrogenase in astrocytes of the postnatal rat hippocampus. 
Hippocampus 14:975-985. 
 
Li T, Ren G, Lusardi T, Wilz A, Lan JQ, Iwasato T, Itohara S, Simon RP, Boison D 
(2008) Adenosine kinase is a target for the prediction and prevention of 
epileptogenesis in mice. The Journal of clinical investigation 118:571-582. 
 
 130 
Liu S, Lu L, Cheng X, Xu G, Yang H (2014) Viral infection and focal cortical 
dysplasia. Annals of neurology 75:614-616. 
 
Miura M (2012) Apoptotic and nonapoptotic caspase functions in animal 
development. Cold Spring Harbor perspectives in biology 4. 
 
Nakanishi T, Kadomatsu K, Okamoto T, Ichihara-Tanaka K, Kojima T, Saito H, 
Tomoda Y, Muramatsu T (1997) Expression of syndecan-1 and -3 during 
embryogenesis of the central nervous system in relation to binding with midkine. 
Journal of biochemistry 121:197-205. 
 
Noh HS, Kim YS, Lee HP, Chung KM, Kim DW, Kang SS, Cho GJ, Choi WS (2003) 
The protective effect of a ketogenic diet on kainic acid-induced hippocampal cell 
death in the male ICR mice. Epilepsy research 53:119-128. 
 
Paquet M, Ribeiro FM, Guadagno J, Esseltine JL, Ferguson SS, Cregan SP (2013) 
Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose 
deprivation-mediated astrocyte apoptosis. Molecular brain 6:9. 
 
Pardo B, Rodrigues TB, Contreras L, Garzon M, Llorente-Folch I, Kobayashi K, 
Saheki T, Cerdan S, Satrustegui J (2011) Brain glutamine synthesis requires 
neuronal-born aspartate as amino donor for glial glutamate formation. Journal of 
cerebral blood flow and metabolism : official journal of the International Society of 
Cerebral Blood Flow and Metabolism 31:90-101. 
 
Queiroz CM, Gorter JA, Lopes da Silva FH, Wadman WJ (2009) Dynamics of 
evoked local field potentials in the hippocampus of epileptic rats with spontaneous 
seizures. Journal of neurophysiology 101:1588-1597. 
 
Rombaldi RL, Serafini EP, Mandelli J, Zimmermann E, Losquiavo KP (2008) 
Transplacental transmission of Human Papillomavirus. Virology journal 5:106. 
 
Schiller JT, Day PM, Kines RC (2010) Current understanding of the mechanism of 
HPV infection. Gynecologic oncology 118:S12-17. 
 
Shafti-Keramat S, Handisurya A, Kriehuber E, Meneguzzi G, Slupetzky K, Kirnbauer 
R (2003) Different heparan sulfate proteoglycans serve as cellular receptors for 
human papillomaviruses. Journal of virology 77:13125-13135. 
 
Shapiro KA, McGuone D, Deshpande V, Sadow PM, Stemmer-Rachamimov A, 
Staley KJ (2015) Failure to detect human papillomavirus in focal cortical dysplasia 
type IIb. Annals of neurology. 
 
 131 
Sun J, Yu JS, Jin S, Zha X, Wu Y, Yu Z (2010) Interaction of synthetic HPV-16 
capsid peptides with heparin: thermodynamic parameters and binding mechanism. 
The journal of physical chemistry B 114:9854-9861. 
 
Sussman D, Ellegood J, Henkelman M (2013a) A gestational ketogenic diet alters 
maternal metabolic status as well as offspring physiological growth and brain 
structure in the neonatal mouse. BMC pregnancy and childbirth 13:198. 
 
Sussman D, van Eede M, Wong MD, Adamson SL, Henkelman M (2013b) Effects of 
a ketogenic diet during pregnancy on embryonic growth in the mouse. BMC 
pregnancy and childbirth 13:109. 
 
Suzuki Y, Toribe Y, Mogami Y, Yanagihara K, Nishikawa M (2008) Epilepsy in 
patients with congenital cytomegalovirus infection. Brain & development 30:420-
424. 
 
Sztiller-Sikorska M, Jakubowska J, Wozniak M, Stasiak M, Czyz M (2009) A non-
apoptotic function of caspase-3 in pharmacologically-induced differentiation of K562 
cells. British journal of pharmacology 157:1451-1462. 
 
Vermeiren C, Hemptinne I, Vanhoutte N, Tilleux S, Maloteaux JM, Hermans E 
(2006) Loss of metabotropic glutamate receptor-mediated regulation of glutamate 
transport in chemically activated astrocytes in a rat model of amyotrophic lateral 
sclerosis. Journal of neurochemistry 96:719-731. 
 
Yudkoff M, Daikhin Y, Nissim I, Horyn O, Lazarow A, Luhovyy B, Wehrli S, 
Nissim I (2005) Response of brain amino acid metabolism to ketosis. Neurochemistry 
international 47:119-128. 
 
Zheng GZ, Lee C, Pratt JK, Perner RJ, Jiang MQ, Gomtsyan A, Matulenko MA, Mao 
Y, Koenig JR, Kim KH, Muchmore S, Yu H, Kohlhaas K, Alexander KM, 
McGaraughty S, Chu KL, Wismer CT, Mikusa J, Jarvis MF, Marsh K, Kowaluk EA, 
Bhagwat SS, Stewart AO (2001) Pyridopyrimidine analogues as novel adenosine 
kinase inhibitors. Bioorganic & medicinal chemistry letters 11:2071-2074. 
 
 
 
 
 
 
